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Abstract 
Background: Breast cancer is the most common cancer found among women of South 
Africa with the prominent effective form of treatment being chemotherapy. Many cancer 
patients receiving chemotherapeutic treatment experience skeletal muscle wasting, 
however, the contribution of muscle wasting to the metastatic properties of breast cancer 
and response to current treatment strategies has not yet been fully investigated. The aims of 
this study were to investigate the reciprocal interactions between mouse breast cancer cells 
(E0771) and mouse myotubes (C2C12) as well as the effects of doxorubicin (DXR) on these 
interactions. 
Methods: Conditioned media was collected from two separate cycles. The initial cycle of 
conditioned media was collected from E0771 breast cancer cells after treatment with/without 
1.6 µM of DXR. Myotubes were then treated with/without DXR as well as conditioned media 
collected during the initial cycle from the E0771 cells. A new series of E0771 cells were then 
treated with/without DXR as well as with the second cycle of conditioned media collected 
from the myotubes. Mitochondrial integrity of myotubes was investigated using MitoSOX™ 
stain analysis while myotube cell viability and integrity was assessed using a Cell Tracker™ 
stain analysis. Cell viability of E0771 cells was assessed with an MTT assay and the 
migratory properties (wound closure) using a migration scratch assay. Western blot analyses 
were used to determined alterations in proliferation, apoptotic, and epithelial-mesenchymal 
transition (EMT) signaling pathways. 
Results: Treatment of myotubes with 1.6 µM of DXR significantly induced mitochondrial 
ROS production (5.580 ± 0.4, p<0.001) when compared to Control but myotube integrity was 
maintained. Treatment of E0771 cells with 1.6 µM of DXR compared to Control significantly 
decreased cell viability (60.354% ± 1.237, p<0.001), significantly increased the 
phosphor/total ERK expression ratio (3.946 ± 0.520, p<0.001), and significantly decreased 
the cleaved/total PARP expression ratio (0.651 ± 0.027, p<0.001). Additionally, a significant 
increase in the percentage of wound closure was also observed in the DXR group (16.049% 
± 1.11, p<0.01) compared to Control after 24-hours. E0771 cells treated with myotube 
conditioned media after treatment of DXR (C.DXR), induced a significant decrease in 
expression of the cleaved/total PARP ratio (0.662 ± 0.097, p<0.01) as well as a significant 
difference in percentage of wound closure (17.19 ± 0.758, p<0.001) compared to C.Control. 
Following treatment of the E0771 cells with myotube conditioned media, harvested after the 
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treatment of conditioned media from DXR treated E0771 cells (C.C.DXR), a significant 
increase in cell viability (121.743% ± 3.442, p<0.05) when compared to C.C.Control. 
Additionally, comparison of C.C.DXR to C.C.Control observed a significant decrease in 
expression of total Akt (65.554% ± 17.55, p<0.05), MCM2 (55.167% ± 14.64, p<0.05), and 
the cleaved/total PARP ratio (0.456 ± 0.111, p<0.001) was observed. 
Conclusion: Investigation of the dynamic interactions between myotubes and breast cancer 
cells revealed novel evidence of the influence of the myotube environments on cancer 
progression. Our study also revealed novel evidence that this myotube environment 
significantly affected the response of breast cancer cells to the chemotherapeutic treatment 
of DXR. These findings identified new mechanisms that may promote breast cancer 
metastasis, which can be utilized to improve chemotherapy in cancer patients. 
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Opsomming  
Agtergrond: Borskanker is die mees algemene kanker wat onder die vroue van Suid-Afrika 
voorkom, met chemoterapie wat tans die mees effektiewe vorm van behandeling is. Baie 
kankerpasiënte wat chemoterapeutiese behandeling ontvang, ervaar skeletspieratrofie, 
maar die bydrae van spierverlies tot metastatiese eienskappe van borskanker asook die 
reaksie op huidige behandeling is nog nie volledig ondersoek nie. Die doel van die studie 
was om ondersoek in te stel na die wederkerige interaksies tussen muis borskankerselle 
(E0771) en muis spiervesels (C2C12) asook die effekte van doxorubicin (DXR) op hierdie 
interaksies. 
Metodes: Voorgeskrewe media is versamel uit twee afsonderlike siklusse. Die aanvanklike 
siklus van gekondisioneerde media is uit E0771 borskanker selle versamel na behandeling 
met/sonder 1.6 µM van DXR. Spiervesels is dan behandel met/sonder DXR sowel as met 
gekondisioneerde media wat tydens die aanvanklike siklus van die E0771-selle versamel is. 
‘n nuwe reeks van E0771-selle is behandel met/sonder DXR en met die tweede siklus 
gekondisioneerde media wat van die spiervesels versamel is. Mitokondriale integriteit van 
die spiervesels is ondersoek deur van MitoSOX™ kleuring met fluoresensie mikroskopie te 
gebruik terwyl die lewensvatbaarheid en integriteit van spiervesels bepaal is met behulp van 
'n Cell Tracker ™ kleuring. Die lewensvatbaarheid van E0771-selle is geassesseer met 'n 
MTT-toets en die migrerende eienskappe (wond sluiting) met behulp van ‘n 
migrasiekrapassessering. Westerse kladanalise is gebruik om veranderinge in proliferasie-, 
apoptotiese- en epiteel-mesenkiemale oorgang (EMT) seinweë te bepaal. 
Resultate Behandeling van spiervesels met 1.6 µM van DXR het 'n aansienlike induksie van 
mitochondriale ROS-produksie (5.580 ± 0.4, p <0.001) gelewer n vergelyking met die 
konrole groep (Control), maar die integriteit van spiervesels het behoue gebly. Behandeling 
van E0771-selle met 1,6 µM DXR in vergelyking met die konrole groep (Control) het die 
lewensvatbaarheid van die selle aansienlik verminder (60.354% ± 1.237, p <0.001), die 
fosfo/totale ERK-uitdrukkingsverhouding (3.946 ± 0.520, p <0.001) laat toeneem en die 
gesplete/totale PARP-uitdrukkingsverhouding (0.651 ± 0,027, p <0,001). Daarbenewens is 'n 
beduidende verskil in die persentasie wondsluiting ook waargeneem (16.049% ± 1.11, p 
<0.01) in vergelyking met die konrole groep na 24 uur. E0771 selle behandel met DXR 
behandelde spiervesel gekondisioneerde media (C.DXR) het 'n beduidende afname in die 
uitdrukking van die gesplete/totale PARP-verhouding (0.662 ± 0.097, p <0.01) sowel as 'n 
beduidende verskil in persentasie wondsluiting veroorsaak (17.19 ± 0,758, p <0.001) n 
vergelyking met die konrole groep (C.Control). Die behandeling van E0771-selle met 
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spiervesel-gekondisioneerde media, na behandeling met gekondisioneerde media van DXR 
behandeled E0771-selle (C.C.DXR), 'n beduidende toename in die lewensvatbaarheid van 
die selle (121.743% ± 3.442, p <0.05) in vergelyking met die konrole groep (C.C.Control). 
Daarbenewens het die vergelyking van C.CDXR tot C.C.Control 'n beduidende afname in 
die uitdrukking van totale Akt (65.554% ± 17.55, p <0.05), MCM2 (55.167% ± 14.64, p 
<0.05), en die gesplete/totale PARP verhouding (0.456 ± 0.111, p <0.001) waargeneem. 
Gevolgtrekking: Ondersoek na die dinamiese interaksies tussen skeletspiervesels en 
borskankerselle het nuwe bewyse getoon van die invloed van die spiervesel-omgewings op 
die verloop van kanker. Ons studie het ook nuwe bewyse getoon dat hierdie spiervesel-
omgewing die reaksie van borskankerselle op die chemoterapeutiese behandeling met DXR 
aansienlik beïnvloed het. Hierdie bevindings het nuwe meganismes geïdentifiseer wat 
metastase van borskanker beïnvloed en nuwe teikens uitgewys wat moontlik chemoterapie 
in kankerpasiënte kan verbeter.  
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Chapter 1 – Literature Review 
Introduction 
Cancer is defined as abnormal and excessive cell growth within tissues or organs (Cheung-
Ong, Giaever & Nislow, 2013). Each year a reported 14 million people worldwide are 
diagnosed with cancer and this number is predicted to increase over time (CANSA, 2018). 
Breast cancer is the most common cancer found among the women of South Africa with 
±19.4 million women at risk (National Cancer Institute, 2015). The hallmarks of cancer 
include: 1) cell proliferation and growth that do not adhere to proper signaling, 2), evasion of 
growth suppression signaling, 3) cell death avoidance, 4) immune destruction avoidance, 5) 
infinite replication, 6) promoting inflammation that benefits tumour, 7) cellular energetics 
dysregulation, 8) instability and mutations in genome, 9) promotion of angiogenesis in 
tumour, and 10) invasion and metastasis activation (Hanahan & Weinberg, 2011). 
Doxorubicin is currently one of the most effective chemotherapeutic agents to treat cancer, 
including breast cancer, and is used for the treatment of cancer in South Africa (Hudis & 
Gianni, 2011). Unfortunately, chemotherapeutic drugs are not specialized agents that only 
target cancer cells. The systemic induction results in a systemic response in all tissues 
including healthy cells. This results in loss of healthy cells and tissues as well the 
development of drug resistance in patients. Skeletal muscle comprises 50% of the total 
human body and has been observed to undergo wasting, known as cachexia, as a response 
to cancer and chemotherapeutic treatment (Surov et al., 2009; Hardee, Montalvo & Carson, 
2017). The contribution of cachexia to the response of breast cancer to current 
chemotherapeutic treatment and metastatic properties has not yet been fully investigated.  
Due to the complex composition and regulation of cancer, research into systemic 
interactions focuses on mechanisms that could be targeted for more effective treatments. 
Investigation into the mammary gland, its cancer, skeletal muscle, and the interactions will 
be discussed in the following review. 
 
 
1.1. Mammary Gland 
The mammary gland is a glandular organ that consists of a variety of cell types that 
undergoes remodeling due to various stages of cell proliferation, differentiation, and 
apoptosis throughout the lifespan of a female. These alterations are in response to stimuli 
from menstrual cycles, pregnancy, lactation and involution (Inman et al., 2015). The 
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mechanisms and pathways present in normal mammary gland development and remodeling 
are observed to be dysfunctional in the progression of breast cancer.  
Normal mammary glands consist of epithelial and non-epithelial compartments. The 
epithelial compartments are heterogeneous as they originate from stem cells. These stem 
cells undergo heterotypic signaling into multiple subpopulations that are able to dynamically 
interrelate (Mareel & Constantino, 2011). The non-epithelial compartments are referred to as 
the stroma, which comprises of resident as well as recruited cells that mainly consists of a 
mesenchymal phenotype. Adipocytes are mesenchymal cells that form the stromal 
compartment that is also known as the mammary fat pad (Mareel & Constantino, 2011). An 
intact basement membrane separates the stroma from the epithelium. Clear separation of 
the epithelial and stromal compartment however, is doubtful due to the ability of epithelial 
cells to express phenotypes similar to stromal cells (Monks et al., 2008). These 
compartments interact in order to regulate embryonic organogenesis, adult maintenance of 
homeostasis in organs as well as cancer development or suppression (Mareel & 
Constantino, 2011; Bissell and Hines, 2011). The mammary gland development involves 
epithelial structures and therefore molecules involved in epithelial cell-cell adhesion, such as 
the E-cadherin/β-catenin complex, have a significant influence in its development (Mareel & 
Constantino, 2011). Endocrine gland interactions also modulate the normal development of 
the mammary gland (Mareel & Constantino, 2011).  
 
1.1.1. Embryonic development 
During the embryonic development phase, a single ectoderm layer expands to form 
mammary lines. These ectoderm cells migrate and form multilayered lens-shaped 
arrangements called placeodes (Sakakura, Nishizuka & Dawe, 1976; Hens & Wysolmerski, 
2005). The placodes develop into bulbs of epithelial cells that are distinct from the 
surrounding dermis. A mammary mesenchyme forms from the condensation of 
mesenchymal cells around the epithelial buds. Subsequently, mammary fat pad precursors 
differentiate on the outside of the first mammary mesenchyme surrounding the epithelial 
compartment (Sakakura, Nishizuka & Dawe, 1976). Epithelium-induced expression of 
hormone receptors found on the mesenchyme modulates organogenesis (Heuberger et al., 
1982.). In male embryos, the activation of androgen receptors within the mesenchyme, 
initiates the degradation of mammary buds while female embryos continue the development 
of the mammary buds with epithelial cell proliferation. This proliferation induces elongation of 
the mammary bud to form a sprout, which enters into the fat pad precursor (Sakakura, 
Nishizuka & Dawe, 1976; Inman et al., 2015). The epidermal cells covering the bud forms 
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the nipple while a lumen develops within the sprout (Inman et al., 2015). A rudimentary 
ductal tree is form from the branching of the sprout into the fat pad (Sakakura, Nishizuka & 
Dawe, 1976). The mammary epithelium at the nipple remains quiescent until the female 
reaches puberty. 
 
1.1.2. Pubertal development 
Hormones and additional factors expressed during puberty induce branching 
morphogenesis, which is the enlargement of the terminal end bud of the epithelial duct 
invading into the mammary fat pad (Lyons, 1958; Williams & Daniel, 1983). These epithelial 
terminal end buds contain multilayered epithelial body cells and epithelial luminal cells 
surrounded by a layer of epithelial cap cells and myoepithelial cells as seen in Figure 1.1 
(Silberstein & Daniel, 1982; Williams & Daniel, 1983; Sternlicht, 2006; Inman et al., 2015). 
These cells undergo epithelial-mesenchymal transition (EMT) as the epithelial cells contain 
mesenchymal properties, in order to invade into the mammary fat pad (Nelson et al., 2006; 
Kouros-Mehr & Werb, 2006). The production and activation of transforming growth factor 
beta (TGF-β) terminates branching morphogenesis into the fat pad, however, the exact 
mechanism is not known (Nelson et al., 2006). During each menstrual cycle of virgin mice 
the epithelium proliferates and undergoes apoptosis (Fata, Chaudhary & Khokha, 2001). 
Figure 1.1: Structure of epithelial terminal end bud in mammary gland during branching 
morphogenesis at puberty development phase. The epithelial duct contains epithelial body cells 
surrounding by myoepithelial cells that attach to the epithelial terminal end bud. This bud contains 
epithelial luminal cells surrounded by epithelial cap cells that undergo transition during branching. 
Scheme reproduced from Inman et al. (2015). 
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1.1.3. Pregnancy development 
During pregnancy, the circulating hormones initiate rapid proliferation of alveolar epithelium 
to form secretory alveoli. In the secretory alveoli of lactating females, the luminal epithelial 
cells that are apically orientated produce and secrete milk proteins into the lumen (Inman et 
al., 2015). Once milk production is decreased due to weaning, the expanded epithelial 
compartments undergo apoptosis. This apoptotic process is known as involution and causes 
the remodeling of the epithelial compartment and surrounding tissue of the mammary gland 
(Monks et al., 2008). 
 
1.1.4. Mammary gland microenvironment 
The microenvironment surrounding the mammary gland cells, such as the stroma and extra-
cellular matrix (ECM), influences the development and function of the mammary gland 
epithelium throughout all phases of development. The ECM regulates epithelial structure 
and function in the mammary gland. Myoepithelial cells are smooth muscle-like cells with an 
epithelial origin and are found on a specialized layer of the ECM known as the basement 
membrane (Inman et al., 2015). Stromal and myoepithelial cells are responsible for the 
synthesis of components of the ECM such as fibronectin, collagens, proteoglycans, and 
laminins. These compounds are not only incorporated into the ECM but also into the 
basement membrane.  
Stromal compartments of the mammary gland consist of dense fat pad precursors during 
embryogenesis, which converts to white fat tissue after birth (Sakakura, Nishizuka & Dawe, 
1976). A reduction in the lipid content of mammary adipocytes is observed during pregnancy 
and lactation. The reservoir of adipose tissue surrounding the epithelial compartments as 
seen in Figure 1.2, is therefore necessary for the production of milk as it is a demanding 
metabolic process (Hovey & Aimo, 2010; Gregor et al., 2013). The endocrine functions of 
adipocytes are understood to influence epithelial growth, epithelium function, and 
communication with multiple cell types to regulate processes within the mammary gland 
(Hovey & Aimo, 2010).  
Fibroblasts are implanted within the fat pad of the stromal compartments. During branching 
morphogenesis, fibroblasts communicate bi-directionally with the epithelium and releases 
proteases, growth factors, and other stimuli (Howard & Lu, 2014). The synthesis of ECM 
components fibronectin, proteoglycans, and collagens is also regulated by fibroblasts. In 
addition, fibroblasts synthesize matrix metalloproteinase’s (MMP’s); enzymes capable of 
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degrading the ECM and releasing growth factors or cytokines present within the ECM, in 
order to alter ECM composition or density (Lühr et al., 2012). 
Figure 1.2: Anatomical structure of mammary gland and surrounding microenvironment. A 
mature mammary gland consists of lactiferous ducts, lactiferous ampulla and lobule. Adipocytes, 
fibroblasts and blood vessels within the surrounding microenvironment promote the development and 
function of the mammary gland. Scheme adapted from medical illustrator Patrick J. Lynch. 
 
The skeletal muscle is located in close proximity to the mammary gland with vascular 
structures and adipocytes communicating between these microenvironments (Figure 1.2). 
During lactation, changes in skeletal muscle metabolism have been observed (Xiao, Grove 
& Smith, 2004), indicating interactions do occur during normal remodeling. The skeletal 
muscle microenvironment and interactions will be discussed later in this chapter. 
 
 
1.2. Breast Cancer 
Cancer develops due to mutations in genes responsible for the regulation of cell proliferation 
and differentiation (Tacar, Sriamrnsak & Dass, 2012). A tumour in the epithelium of the 
mammary gland is known as breast cancer and carcinomas commonly occur within the 
ducts, terminal ducts and lobules (Russo, Tay & Russo, 1982). According to the Cancer 
Association of South Africa and National Cancer Institute, breast cancer is the most common 
cancer found in women in South Africa with ±19.4 million women at risk (CANSA, 2010; 
National Cancer Institute, 2015). Globally, a reported 1.5 million new cases of breast cancer 
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is diagnosed every year with a prediction that in 2020, 1.7 million women will be diagnosed 
with breast cancer (CANSA, 2018). Factors such as inherited mutations, unsatisfactory 
diets, tobacco and radiation promote the possibility of developing cancer (Tacar, Sriamrnsak 
& Dass, 2012). The alterations in mammary cells and morphology during early menstruation 
induction, late pregnancy, and a nulliparous uterus are thought to be factors involved in 
increased risk of breast neoplastic development while early pregnancy induces a protective 
effect against neoplastic development (Russo, Tay & Russo, 1982). While there is an 
absence of updated registries in South Africa, it is still evident that breast cancer has a high 
mortality risk, therefore effective treatment strategies are required. 
 
1.2.1. The structure of breast tumours 
A breast tumour is composed of two compartments: an epithelial compartment that consists 
of proliferating cells while the stroma consists of blood vessels and connective tissue (Tacar, 
Sriamrnsak & Dass, 2012). The expression of molecules that is important for cell 
proliferation and other processes during embryogenesis are down regulated in adult tissue. 
These molecules, however, have been observed to be re-expressed in tumours (Mareel & 
Constantino, 2011). Tumour cell masses can be sub-divided into two categories, namely 
benign and malignant tumours. A benign tumour develops when cancer cells have not 
proceeded to disperse into tissue surrounding the tumour. The tumour is confined to a 
specific area of growth and maintains a lower risk to an individual. Malignant tumours are 
able to invade into surrounding tissue resulting in the development of more complex tumours 
and poor patient prognosis. Mutations in various signaling pathways may result in cancer 
and tumour development. Triple negative breast cancer (TNBC) is the most aggressive form 
of breast cancer and is commonly associated with advanced tumour grade, p53 and breast 
cancer 1 and 2 genes (BRCA 1/2) mutations as well as basal cytokeratin’s alterations 
(Bernier & Poortmans, 2016). The tumour suppressor protein p53 regulates the cell cycle in 
normal cells and terminates proliferation when the cell has damage or physiological stress. 
Apoptosis is then induced to remove this harmful cell. In cancer conditions, p53 is 
dysfunctional allowing proliferation of damaged and stressed cells as well as inhibition of 
apoptosis (Hahn & Weinberg, 2002). Invasive breast cancer, such as TNBC, was observed 
to express markers often secreted by normal epithelial breast cells (Badve et al., 2011). 
These aggressive cancers display increased necrotic areas with mitotic manifestations, 
recurrence of cancer, and the development of distant metastases (Bernier & Poortmans, 
2016). Mutations within signaling pathways regulating cell proliferation, cell death or cell 
development promote the development and progression of cancer. The dysregulation of 
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these signaling pathways that promote tumour formation will be discussed in the proliferation 
section. 
 
1.2.2. Classification 
Breast tumours are classified according to the original tissue in which it develops, the 
morphology of the cell, and any molecular signatures that may be present. Adenocarcinoma 
is a broad term of cancer developing in glandular cells, these cells are found in the breast, 
prostate and lungs. Invasive ductal carcinoma is malignant cancer that develops in the 
epithelial lining of the mammary ducts, while the benign tumours are known as ductal 
carcinoma in situ. Cancer that progresses within the milk producing glands, the lobules, is 
known as a lobular carcinoma (Sakakura, Nishizuka & Dawe, 1976). This cancer may also 
be invasive or in situ. 
Grading of breast cancer occurs according to the differentiated state of the cancer. Tumours 
with the worst prognoses are comprised of poorly differentiated or undifferentiated cells 
(Wong et al., 2018). Ben-Porath et al., (2008) analysed the expression profiles of 1211 
breast tumours using six independent studies.  They demonstrated that embryonic stem cell-
like gene expression profiles in poorly differentiated tumours were associated with poor 
prognosis and patient survival. These findings were substantiated in bladder carcinomas and 
high-grade glioblastomas.  
 
1.2.3. Treatments 
Endocrine gland interactions modulate the normal development of the mammary gland 
therefore the hormones that regulate these processes may influence breast neoplasms and 
can serve as potential targets for effective cancer treatment (Mareel & Constantino, 2011). 
Cancer cells that are estrogen and/or progesterone positive contain receptors specific for 
these hormones. This enables them to be treated with hormone therapy while those 
expressing human epidermal growth factor receptor type 2 (HER2) receptors can be treated 
with interventions targeting this receptor (National Cancer Institute, 2015). TNBC does not 
express estrogen, progesterone, or HER2 receptors, thus rendering targeted hormonal 
therapies ineffective (Badve et al., 2011; Foulkes, Smith & Reis-Filho, 2010; Bernier & 
Poortmans, 2016). Chemotherapy with the use of chemical agents has been successful in 
treating breast cancer including TNBC, however, cancer patients undergoing this treatment 
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can sometimes still have a poor outcome (Foulkes, Smith & Reis-Filho, 2010). Treatment of 
breast cancer using chemotherapy will be discussed in the doxorubicin section. 
 
1.2.3. Metastasis 
Cancer cells can exhibit metastatic properties, such as the secretion of MMP enzymes, 
which are able to disrupt the normal tissue (Croce, 2008). Cancer cells with these properties 
are able to invade into blood or lymphatic circulation systems and consequently spread 
throughout the body. It was found that gene expression profiles of metastatic breast cancer 
cell lines exhibit proteins that promote organ-specific metastasis (Mareel & Constantino, 
2011). Sentinel lymph nodes are considered to be the initial step in breast cancer metastasis 
due to the nodes being the primary site where tumour antigens may be received (Mareel & 
Constantino, 2011). Metastatic cell lines, such as MDA-MB-231, may express high quantities 
of certain metastasis-associated molecules like the CD73 transmembrane protein. This 
protein is involved in normal lymphocyte homing processes and promotes lymph node 
metastasis (Lee et al., 2003). Further discussion will be done of the invasive and metastatic 
properties of breast cancer in the invasion and metastatic section. 
 
 
1.3. Doxorubicin 
Chemotherapy, also known as anti-neoplastic therapy, remains the most common form of 
anti-cancer therapy for multiple cancer types. Treatment is given to patients through 
intravenous, intra-vesical, intra-arterial or oral diffusion depending on the type of cancer. For 
chemotherapy to be considered effective, cancer cells must show inhibition of cell 
proliferation and induction of cell death. Chemotherapeutic agents are classified into groups 
due to differences in chemical composition and anti-neoplastic function. Alkylating 
chemotherapeutic agents target and damage DNA directly to inhibit cancerous cell 
proliferation. Anti-metabolites target DNA and RNA synthesis where it substitutes the 
standard building blocks required for appropriate replication and transcription of DNA (Tacar, 
Sriamrnsak & Dass, 2012). Topoisomerase inhibitor agents target the topoisomerase 
enzyme preventing DNA double strand separation and mitotic inhibitor agents target the 
microtubule spindle machinery, thus inhibiting mitosis. Lastly, anti-tumour antibiotics, such 
as anthracyclines, target DNA replication enzymes, however, its function is not dependent 
on specific cell cycle phases (Shepherd, 2003). 
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Doxorubicin (DXR) is an anthracycline chemotherapeutic agent used to treat several 
different tumours including TNBC (Hudis & Gianni, 2011), lung (Melguizo et al., 2015), 
ovarian (Ye, Karim & Loh, 2014) and colon cancer (Lüpertz et al., 2010). DXR is observed to 
be one of the most effective chemotherapeutic agents approved by the Food and Drug 
Administration (FDA) (Carvalho et al., 2009). Anti-neoplastic properties include targeting 
cells undergoing rapid proliferation and the reduction of cancer progression. 
 
1.3.1. Structure and metabolism 
DXR is chemically composed of an aglycone as well as a sugar moiety classifying it as a 
non-selective class I anthracycline. A tetracyclic ring with quinine-hydroquinone adjacent 
groups and a methoxy substituent short side chain trailed by a carbonyl group form the 
aglycone moiety (Hilmer et al., 2004). Daunosamine, the sugar moiety, is characteristic of a 
3-amino-2, 3, 4-trideoxy-L-fucosyl component attached to one of the tetracyclic rings of the 
aglycone with a glycosidic bond (Figure 1.3) (Hilmer et al., 2004). 
Following treatment, cells rapidly take up DXR as the chemical half-life of DXR is 3-5 
minutes (New Zealand Medicines and Medical Devices Safety Authority, 2014). The 
elimination of DXR from tissue requires more time hence its terminal half-life is 20 - 48 
hours. Injection of DXR into cancer patients is completed with a steady-state distribution flow 
of 20 to 30 L/kg (New Zealand Medicines and Medical Devices Safety Authority, 2014). This 
flow rate attempts to promote effective anti-cancer effects and decrease toxicity in patients 
(Zheng et al., 2006). The liver chemically modifies DXR and its major metabolite, 
Doxorubicinol. Both these molecules undergo acid-catalyzed hydrolysis of their glycosidic 
bonds, eliminating the sugar component. This process forms doxorubicinone from DXR and 
doxorubicinolone from doxorubicinol.  
Figure 1.3: The chemical structure of the chemotherapeutic agent doxorubicin. Structure 
includes an aglycone attached to sugar moiety by a glycosidic bond. Sourced from Wang et al. 
(2001). 
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1.3.2. Mechanisms of action 
After being injected into a patient, DXR passively diffused into cells until the extracellular 
concentration is less than the intracellular concentration (Wang et al., 2000). While 
antracyclines customarily target DNA replication enzymes, DXR targets topoisomerase I and 
II, as well as intercalates itself into DNA to inhibit uncoiling (Tacar, Sriamrnsak & Dass, 
2012).  
Initial mechanism of action involves the binding of DXR to the 20S subunit of a proteasome 
in the cytoplasm, forming a DXR-proteasome complex (Figure 1.4). The complex 
translocates into the nucleus through the nuclear pore. The affinity of DXR to bind to DNA is 
greater than the proteasome, therefore, DXR dissociates from the complex in order to bind 
to DNA (Hilmer et al., 2004). It intercalates itself into DNA, which inhibits and dysregulates 
DNA and RNA polymerase functions, preventing DNA and RNA transcription (Volkova & 
Russell, 2011; Shaw & Cantley, 2006). Intercalation also prevents the uncoiling and 
separation of DNA (Minotti et al., 2004). The lipophilic and DNA intercalating properties of 
DXR ensures it remain within the nucleus of the cells. DXR also has a high affinity for 
components associated with the mitochondria and the complexes of the electron transport 
chain (ETC) (Gilliam et al., 2012). It has been observed that DXR binds to mitochondrial 
DNA, and not only nuclear DNA (Ashley & Poulton, 2009). The inability to pass the blood-
brain barrier prevents DXR from being a viable treatment for brain cancer (Tacar, 
Sriamrnsak & Dass, 2012). 
The production of reactive oxygen species (ROS) is another mechanism in which DXR 
induces its effects as shown in Figure 1.4. The chelation of intracellular iron with DXR 
activates a Fenton-type reaction and the production of highly reactive hydroxyl radicals. 
When molecular oxygen is present, redox cycle reactions occur with flavoprotein reductase 
that produces superoxide (Tacar, Sriamrnsak & Dass, 2012). Additionally, DXR binds 
directly to plasma proteins of the cell membrane inducing an enzymatic electron reduction 
that produces reactive hydroxyl free radicals that induce DNA damage and promote cell 
death (Tacar, Sriamrnsak & Dass, 2012). These effects make DXR an effective 
chemotherapeutic agent, however, it is also responsible for negative toxic effects. 
The apoptotic pathway is directly influenced by DXR through Bcl-2/Bax interactions that will 
be discussed in the proliferation section (Leung & Wang, 1999). Additionally, the hyper-
activation of poly (ADP-ribose) polymerase (PARP) can also occur promoting increased 
DNA repair and therefore avoidance of cell death  (Tacar, Sriamrnsak & Dass, 2012). 
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Figure 1.4: Basic mechanisms of action induced by doxorubicin. The mechanisms of action 
include the formation of a doxorubicin (DXR)-proteasome complex and translocation into the nucleus. 
Here DXR binds and intercalates into the DNA inhibiting transcription. The production of reactive 
oxygen species (ROS) is another mechanism in which the mitochondria and DNA damage occurs. 
Additionally, disruption of the Bcl-2/Bax ratio and hyper-activation of PARP inhibits apoptosis. 
Sourced from Tacar, Sriamrnsak & Dass (2012). 
 
1.3.3. Negative side effects of chemotherapy 
Chemotherapeutic drugs are not specialized agents that specifically target cancer cells. The 
systemic induction results in a systemic response affecting all tissues including healthy cells. 
Side effects, such as nausea, hair loss, fever, rashes and appetite alterations are a concern 
when treating patients with chemotherapeutic interventions (Coates et al., 1983). The 
continuous administration of DXR into veins results in the thickening of vein walls, known as 
phlebosclerosis. The leakage of DXR out of the administration vein into the surrounding 
tissue is known as extravasation and causes an increase in fibrous components and 
inflammation in the tissue (Carvalho et al., 2009). Cells that undergo rapid proliferation, such 
as mammary cells during pregnancy or immune cells, are easily targeted by chemotherapy 
and undergo cell death. (Shepherd, 2003). Leukocytes and bone marrow precursors are 
examples of rapid proliferating cells affected, as the concentration of DXR in these cells is ± 
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500 times greater than what is found in the plasma (Tacar, Sriamrnsak & Dass, 2012). This 
promotes immunosuppressive side effects in cancer patients (Weir, Liwski & Mansour, 
2011). Due to the metabolic processes that occur in the liver, it has been observed to 
accumulate DXR (Tacar, Sriamrnsak & Dass, 2012). The metabolism results in significant 
ROS production that causes DNA damage and lipid peroxidation. This induces tissue 
damage and cell death in the liver. Accumulation of the drug within the heart results in 
cardiotoxicity, the most harmful consequence of this therapy. DXR targets brain natriuretic 
peptide (BNP) and atrial natriuretic peptide (ANP) within cardiomyocytes (Shi et al., 2011). 
This induces cardiac hypertrophy in cancer patients. Mitochondria present within the cardiac 
muscle are also targeted by DXR by altering mitochondrial protein expression and ROS 
production (Sishi et al., 2013). Cardiotoxicity may lead to pericarditis, arrhythmias and left 
ventricular dysfunction as well as stress-induced cardiomyopathy within these patients 
depending on severity of toxicity and individual parameters (Volkova & Russell, 2011). 
Mortality in breast cancer patients has been observed to occur due to heart failure decades 
after the last chemotherapeutic treatment was given (Harake et al., 2012).  
 
1.3.4. Resistance to chemotherapy 
A concern in cancer intervention using current anti-cancer agents is the increased 
occurrence of drug resistance. Resistance to chemotherapeutic agents, especially 
doxorubicin, is common after prolonged treatment in patients including those with TNBC 
(McCubrey et al., 2007; Bernier & Poortmans, 2016). DXR and other chemotherapeutic 
agents require active proliferation of cancer cells as this exposes the DNA. Within tumours, 
cancer cells are at various phases within the cell cycle and sometimes even exhibit a 
reduced growth rate due to limitations of space and nutrients (Tacar, Sriamrnsak & Dass, 
2012). This results in an ineffective response in cancer cells and the development of 
resistance. Drug resistance can also be induced where there is an increase in positive 
regulators of cell proliferation activity where cell death is inhibited, where tumour 
suppressors are reduced or where survival factors within cancer cells are increased (Chen 
et al., 2014). Signalling pathways that promote cell survival in response to ROS (McCubrey 
et al., 2007) may promote resistance and cell proliferation after DXR treatment. The 
influence of specific signalling pathways on the initiation of drug resistance will be discussed 
in the proliferation section.  
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1.4. Proliferation Signaling 
Epithelial cells in the body undergo continuous cycles of growth and death. Damaged cells 
are normally repaired or removed during the cell cycle. However, defects in the cell cycle or 
gene mutations can lead to cells dividing uncontrollably. Hyperplasia is a condition where 
cells are able to proliferate at increased rates but where normal morphology remains 
(Sherwood, 2013). When these cells experience a change in morphology and structure 
within tissue, the condition is known as dysplasia (National Cancer Institute, 2015). Signaling 
pathways determine whether cells are proliferating or quiescent (Duronio & Xiong, 2013). 
Cancer cells develop when the cells are able to multiply unsuppressed and do not respond 
to signals within the body to cease growth (Peiris-Pagès et al., 2016; Tacar, Sriamrnsak & 
Dass, 2012). Cell proliferation that is not regulated by appropriate signals and infinite 
replication are hallmarks of cancer (Hanahan & Weinberg, 2011). 
 
1.4.1. The cell cycle 
The cell cycle consists of the first gap (G1) phase, DNA synthesis (S), second gap (G2) 
phase and mitosis (M) phase. Each of these phases is controlled by certain cyclin-
dependent kinases (CDKs) and their respective cyclins (Duronio & Xiong, 2013; Fei & Xu, 
2018). Pathways involved in stress response, differentiation, quiescence, and senescence 
initiates the G1 phase. At the end of this phase, Cyclin-D-CDK4/6 and cyclin-E-CDK2 
initiates the G1/S phase transition by phosphorylating proteins in the Retinoblastoma (RB) 
pathway (Ewen et al., 1993; Akiyama et al., 1992). If no DNA damage is present, the cell 
proceeds to enter the S phase, where the DNA is replicated. The G2 phase follows where 
the cell ensures the successful completion of DNA synthesis and starts preparing for the 
next phase. The end of this phase and the beginning of the M phase is regulated by cyclin-
B-CDK1 (Duronio & Xiong, 2013. The cell divides during the M phase before entering back 
to the G1 phase. Quiescence is achieved when the cell exits the G1 phase and enters into 
the G0 phase. Differentiated cells such as skeletal muscle cells enter into the G0 phase and 
remain metabolically active for a long period of time. Developmental defects and cancer may 
occur due to the disruption of this mechanism (Sherr, 1996) or other alterations in CDKs and 
cyclins (Fei & Xu, 2018). The phosphoinositide 3-kinase (PI3K)-Akt and the extracellular 
signal-regulated kinases (ERK) pathways regulate the expression and ubiquitination of the 
G1 cyclins and therefore regulate the progression of the cell cycle.  
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1.4.2. PI3K/Akt pathway 
The phosphoinositide-3-kinase (PI3K)/Akt pathway is composed of various components that 
regulate its multiple steps as indicated in Figure 1.5. This signaling pathway regulates 
downstream effects such as cell growth, cell proliferation, transcription, protein synthesis, 
cell survival, and cell death (Hemmings & Restuccia, 2012). Due to the numerous stimuli 
and targets of Akt, tumour development is significantly influenced by mutations or 
dysfunctions in the pathway. 
The binding of the required cytokine or growth factor to specific receptor tyrosine kinases 
(RTK) on the cell membrane causes phosphorylation of the receptor.  This causes a 
transformational change allowing the regulatory subunit of PI3K, subunit p85, to bind to the 
receptor (Blalock et al., 1999). The catalytic subunit of PI3K, p110, is then also recruited and 
activated. Complete activation of PI3K induces the membrane localization and conversion of 
phosphatidylinositol 4,5 bisphosphate (PIP2) into phosphatidylinositol 3, 4, 5 trisphosphate 
(PIP3) (Chang et al., 2003). This conversion localizes phosphoinositol-dependent kinase-1 
(PDK1) to the cell membrane where it recruits Akt to the cell membrane and phosphorylates 
it on Thr308 (Hemmings & Restuccia, 2012). The Ser473 phosphorylation site on Akt is 
additionally phosphorylated by mammalian target of rapamycin complex 2 (mTORC2) in 
order for full activation (Manning & Toker, 2017) (Figure 1.5). Akt, also known as Protein 
Kinase B (PKB), is a significant protein in the PI3K-Akt pathway that has numerous 
downstream effects after it is phosphorylated that promote cell growth and proliferation. The 
growth-promoting effects of PI3K are regulated by phosphatases that dephosphorylate PIP3, 
therefore, inhibiting downstream effects (Steelman, Bertrand & McCubrey, 2004). These 
phosphatases are PTEN (Phosphatase and tensin homologue deleted on chromosome 10) 
and SHIP-1/2 (Src homology 2 (SH2) containing phosphatases 1 and 2), which are encoded 
by tumor suppressor genes (Wu et al., 1998; Taylor et al., 2000). 
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Figure 1.5: Activation of PI3K/Akt pathway and downstream effects. The PI3K/Akt pathway is 
initiated by a cytokine or growth factor binding to a RTK. PI3K then binds to the RTK and undergoes 
activation before phosphorylating PIP2 into PIP3. PDK localizes to the cell membrane and 
phosphorylates Akt at Thr308 while mTORC2 phosphorylates at Ser473. Following its activation, Akt 
is able to activate downstream effects including the ERK pathway, phosphorylation of p21 and IKK, 
transcription of CREB well as inhibition of caspase 9. Scheme reproduced from Hemmings & 
Restuccia (2012). 
 
Selected downstream effects of activated Akt are represented in Figure 1.5. In 
mesenchymal cells, Akt has been shown to phosphorylate protein 21 (p21). Expression of 
p21 is responsible for the progression of the cell cycle and DNA synthesis through 
expression and activation of CDK and cyclins (Ghoudhury et al., 1997). Activated Akt may 
also induce the transcription of cAMP response element-binding protein (CREB) and 
phosphorylation of inhibitor κβ kinase (IKK) (Nicholson & Anderson, 2002). Phosphorylated 
IKK induces phosphorylation and degradation of the protein inhibitor of κβ (I-κβ). This is 
significant as before phosphorylation, I-κβ binds to the transcription factor nuclear factor 
kappa-light-chain-enhancer of activated β cells (NF-κβ) and localizes it to the cytosol 
rendering it inactive (Chang et al., 2003). Upon the degradation of I-κβ, NF-κβ is localized to 
the nucleus where transcription of targeted genes occurs. Anti-apoptotic genes are induced 
by NF-κβ activation thereby inhibiting apoptosis (Wang, Mayo & Baldwin, 1996). The 
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inactivation of Raf, Bad, pro-caspase 9, and other apoptotic proteins is also regulated by Akt 
activity (Chang et al., 2003; McCubrey et al., 2007).  
The dysregulation of PI3K has been observed in the development and progression of cancer 
such as breast cancer, prostate cancer, lung cancer, and melanomas (Chang et al., 2003; 
McCubrey et al., 2007). Continuous phosphorylation of p21 by Akt induces an unregulated 
cell cycle due to high expression of CDK and cyclins (Ghoudhury et al., 1997). Abnormal 
NF-κβ transcription of pro-apoptotic proteins due to the reduction in I-κβ inhibition also 
promotes cell survival (Wang, Mayo & Baldwin, 1996). Activated Akt additionally influences 
the regulation and expression of hormone receptors; therefore, high expression of Akt 
promotes resistance to hormone therapy (Shou et al., 2004; Frogne et al., 2005). Mutations 
in PI3K phosphatases may promote the continuous activation of PIP3 and promote tumour 
development or progression (Wu et al., 1998; Taylor et al., 2000).  
 
1.4.3. ERK pathway 
The mitogen-activated protein kinase (MAPK) pathway is also known the ERK pathway. Cell 
growth and survival is promoted by the activation of the ERK pathway (Lu & Xu, 2006), 
however, pro-apoptotic induction has also been observed under certain conditions. This 
pathway is composed of a cascade of reactions from the cell membrane to the nucleus in 
order to phosphorylate and activate the transcription factors to induce specific gene 
expression such as cyclin D expression (Morrison, 2012; Yamaguchi et al., 1995).  
Specific integrins and growth factors that are involved in cell growth and differentiation 
induce the activation of the ERK signaling cascade represented in Figure 1.6 (Yee, Weaver 
& Hammer, 2008; Renshaw, Ren & Schwartz, 1997).  The binding of these molecules 
activate specific receptors on the cell membrane inducing the activation of the growth factor 
receptor-bound protein 2 (Grb2) / son of sevenless (SOS) coupling complex (McCubrey et 
al., 2007). This complex stimulates the exchange of guanine diphosphate (GDP) to 
guanosine triphosphate (GTP) by Ras. Ras is a GTP-binding protein that undergoes a 
conformational change and becomes active with the exchange of GDP. Raf, an enzyme 
from the serine/threonine-specific protein kinase family, contains multiple phosphorylation 
regulation sites that undergoes phosphorylation and dephosphorylating on various domains 
(Fabian, Daar & Morrison, 1993). After the activation of Ras, Raf is recruited to the plasma 
membrane and undergoes phosphorylation. Mitogen-activated protein kinase kinase 2 
(MAP2K2), also known as mitogen-activated protein kinase/ERK kinase (MEK) is a duel 
specificity kinase that is activated by the phosphorylation of the serine residues in its 
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catalytic domain by Raf (Alessi et al., 1994). Active MEK1 and MEK2 phosphorylate ERK 1 
and 2 (McCubrey et al., 2007). ERK 1 and ERK 2 are regulated independently with ERK 2 
being linked with proliferation while ERK 1 inhibits ERK 2 in specific cells (Pouysségur, 
Volmat & Lenormand, 2002). Phosphorylated-ERK downstream effects represented in 
Figure 1.6 include activation of the transcription factor CREB and phosphorylation of IKK, 
which regulates the activation of NF-κβ (Nakano et al., 1998). 
 
Figure 1.6: Activation of ERK pathway and downstream effects. The ERK pathway is initiation by 
the binding of an integrin or growth factor to a receptor that activates the Grb2/SOS coupling complex. 
This complex stimulates Ras to exchange GDP to GTP in order to become activated. Activated Ras 
phosphorylates Raf allowing for the stimulation of the PI3K/Akt pathway and phosphorylation of 
MEK1/2. Activated MEK1/2 phosphorylates and activates ERK 1/2 initiating its downstream effects, 
which include the transcription of CREB, phosphorylation of IKK and Bad as well as induction of EMT 
Scheme reproduced from Chang et al. (2003).  
 
The dysregulation of ERK was observed to be involved in pathogenesis, progression and 
development of cancer (Zhu et al., 2007; Fang & Richardson, 2005). Approximately 30% of 
human cancers are associated with constitutively active Ras proteins (McCubrey et al., 
2007). Normal activation of Ras has been observed to influence the PI3K/Akt pathway as 
Ras promotes the localization of PI3K subunit p110 to the membrane and its activation 
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(Rodriguez-Viciana et al., 1996). This promotes the downstream effects of the PI3K/Akt 
pathway. Cell growth, cell cycle arrest, and apoptosis are associated with an overexpression 
of active Raf proteins (Hoyle et al., 2000). The variety of responses is a result of the specific 
isoform of Raf being overexpressed as A-Raf and Raf-1 promote cell proliferation while B-
Raf promotes cell growth arrest (McCubrey et al., 2007). Mutation of B-Raf was observed in 
approximately 7% of cancers (Garnett & Marais, 2004). The post-translational 
phosphorylation of molecules involved in the regulation of apoptosis, such as Bad, caspase 
9 and Bcl-2, is also influenced by Raf and ERK activity (Weinstein-Oppenheimer et al., 
2001). MEK regulates the protection of cells from oxidative stress and therefore dysfunction 
of MEK can promote resistance to ROS-dependent treatments, such as DXR (McCubrey et 
al., 2007). Additionally, epithelial cells, breast cancer cells, and fibroblasts have shown TGF-
β facilitated activation of ERK which may promote the induction of EMT and cancer 
progression (Davies et al., 2005). 
 
1.4.4. Mini-chromosome maintenance proteins 
Replication of DNA consists of various components to maintain the integrity and stability of 
the genome. Mini-chromosome maintenance proteins (MCM) exhibit ATPase activity 
(Bochman & Schwacha, 2009) and play a role in recruitment of proteins involved in DNA 
replication as well as the formation of replication forks. The MCM proteins are responsible 
for the initiation and formation of pre-replicative complexes during the late M and early G1 
phase of the cell cycle. Following the formation of pre-replicative complexes, MCM proteins 
are phosphorylated by Dbf4-dependent kinase (DDK) and CDKs (Fei & Xu, 2018). 
Phosphorylation induces the recruitment of GINS (Go, Ichi, Ni, and San) and Cdc45 to the 
MCM proteins, which forms the Cdc45-MCMs-Gins (CMG) replicative helicase complex 
(Bruck & Kaplan, 2015; Yeeles et al., 2015).  
Replication checkpoints, transcription, and RNA splicing have also been observed to be 
regulated by MCM proteins (Stead et al., 2012; Li et al., 2011; Chen et al., 2014). The 
variety of downstream effects is due to MCM proteins containing several phosphorylation 
sites specific for kinases. The three kinases regulating MCM phosphorylation are cell 
division cycle (Cdc) kinases, CDKs, and ataxia telangiectasia/ ATM-and-RAD3-related 
proteins (ATM/ATR) (Fei & Xu, 2018). Each kinase phosphorylates specific sites within 
certain MCM proteins for the required function to occur. The phosphorylation of MCM2 by 
serine-threonine kinase Cdc7 at Ser27, Ser41, and Ser139 results in the initiation of DNA 
replication and promotion of ATPase activity while phosphorylation at Ser5 is needed for the 
pre-replicative complexes during the re-entry of the cell cycle (Stead et al., 2012). The 
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MCM2 chromatin loading properties are regulated by Cdc7 phosphorylation of Ser40, Ser53, 
and Ser108 (Chen et al., 2014).  Cdc7 phosphorylation of MCM4 alternatively promotes the 
binding with CdC45 to the chromatin (Li et al., 2011), which is important for the induction of 
DNA replication and cell growth as previously described.  
When the cell enters into the M phase, CDK2 phosphorylates MCM4 at Ser3, Thr7, Ser32, 
Ser54 and Thr110 in order to decrease MCM complex chromatin loading preventing DNA 
replication to re-occur during mitosis (Tudzarova et al., 2016). Phosphorylation of MCM4 at 
Ser3, Thr7, Thr19, Ser54, Ser88, and Thr110 with Cdk2 further inhibits the MCM complex 
and reduces DNA helicase activity (Bochman & Schwacha, 2009; Moritani & Ishimi, 2013). 
The slowing or delaying of replication forks is known as replication stress (Fei & Xu, 2018). 
The majority of mutations resulting in genomic instability and tumour development occur as 
a result of replication stress (Tubbs & Nussenzweig, 2017).  
ATM and ATR regulate this by stabilizing DNA replication forks and activating checkpoints in 
the cell cycle (Fei & Xu, 2018). DNA damage due to factors such as ultraviolet (UV) light and 
ionizing radiation (IR) induces replication stress that initiates the phosphorylation of Ser108 
on MCM2. The replication fork is then a stabilized and delayed allowing cell to repair DNA 
damage (Cortez, Glick & Elledge, 2004). Abnormal MCM phosphorylation induces mutations 
in DNA replication and progression of the cell cycle, which influences development of 
diseases such as cancer (Fei et al., 2017). The upregulation of the PI3/Akt pathway has also 
been shown to directly phosphorylate MCM2 as a result of Akt activity (Chang et al., 2003). 
 
 
1.5. Evasion of Apoptosis 
Apoptosis, first described by Kerr, Wylie & Currie (1972), is a cell death mechanism that 
ensures accurate embryogenesis and homeostasis in healthy tissue. This process is 
regarded as a form of programmed cell death as it is not only regulated by intracellular 
signals but also genetically (Nishida, Yamaguchi & Otsu, 2008). It is an energy-dependent 
mechanism composed of cysteine proteases known as caspases that require precise 
proteolysis for cleavage and activation (Kruidering & Evan, 2000; Martin & Green, 1995). 
Removal of old or DNA damaged cells occurs as a result of apoptotic mechanisms, with 
modest tissue disruption due to absence of inflammation induction (Elmore, 2007). 
Regulation of the apoptotic mechanism as shown in Figure 1.7 is composed of three 
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pathways: extrinsic death receptor pathway, intrinsic mitochondrial pathway, and execution 
pathway. 
 
1.5.1. Extrinsic death receptor pathway 
Induction of the extrinsic death receptor pathway, represented in Figure 1.7 is stimulated 
when the required extracellular death ligand binds to a death receptor on the plasma 
membrane of a cell. These receptors contain a cytoplasmic domain known as the death 
domain (DD). Combination of the ligand and receptor initiates trimerization of receptors 
forming a death complex (Ouyang et al., 2002). A protein that contains a corresponding DD 
to the receptor and pro-caspase 8 is recruited to the death complex initiating formation of a 
death-inducing signaling complex (DISC) (Kischkel et al., 1995). Cleavage and activation of 
pro-caspase 8 by DISC results in the formation of cleaved caspase 8. This active caspase 
protein contains a death effector domain (DED), which is able to induce the execution 
pathway, which will be discussed later (Ouyang et al., 2012). The binding of cellular FLICE 
(FADD-like IL-1β-converting enzyme)-inhibitory protein (c-FLIP) to the death domains and 
pro-caspase 8 inhibits the extrinsic pathway (Scaffidi et al., 1999). 
 
1.5.2. Intrinsic mitochondrial pathway 
Mitochondrial pro-enzymes regulate the intrinsic pathway. Induction of this pathway occurs 
by stimuli, such as toxins, free radicals or hypoxia, or due to the absence of growth factors, 
cytokines, and hormones that suppress cell death (Elmore, 2007). Bcl-2 (B-cell lymphoma 2) 
is a family of pro-apoptotic and anti-apoptotic molecules that regulate apoptosis (Ouyang et 
al., 2012). The pro-apoptotic molecules include Bad, Bax, Bid, and Bcl-Xs while anti-
apoptotic molecules are Bcl-2, Bfl-1, Mcl-1, and Bcl-XL. An elevated Bcl-2/Bax ratio 
corresponds with the onset of apoptosis (Tacar, Sriamrnsak & Dass, 2012). Upon 
stimulation, the pro-apoptotic molecules are activated by dephosphorylation and cleavage 
before being translocated to the mitochondrial membrane (Shamas-Din et al., 2011). These 
molecules, such as Bad, then promote the opening of the mitochondrial permeability 
transition (MPT) pore or bind to anti-apoptotic molecules rendering them ineffective (Yang et 
al., 1995; Elmore, 2007). Opening of the MPT leads to a reduction in the outer mitochondrial 
transmembrane potential resulting in the release of cytochrome c into the cytosol (Elmore, 
2007). In the cytosol, apoptotic peptide activating factor-1 (Apaf-1) and pro-caspase 9, both 
containing caspase activation and recruitment domains (CARDs), bind each other through a 
CARD-CARD interaction and subsequently binds cytochrome c to form the apoptosome 
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complex (Figure 1.7) (Kurokawa & Kornbluth, 2009). The apoptosome cleaves pro-caspase 
9 forming cleaved caspase 9. Similar to cleaved caspase 8, cleaved caspase 9 contains a 
DED that induces the execution pathway (Ouyang et al., 2012). 
Figure 1.7: Regulation of apoptosis: extrinsic, intrinsic, and execution pathways. The extrinsic 
pathway is regulated by extracellular death ligands while the intrinsic pathway is regulated by 
mitochondrial pro-enzymes. Activation of these pathways may result in the activation of the execution 
pathway and induction of apoptosis. Scheme reproduced from Elmore (2007). 
 
 
1.5.3. Execution pathway 
The execution pathway is induced by cleaved caspase 8 from the extrinsic pathway and 
cleaved caspase 9 from the intrinsic pathway (Figure 1.7). These proteins activate pro-
caspase 3 through cleavage forming cleaved caspase 3. Poly (ADP-ribose) polymerase 
(PARP) is found in the nucleus of a cell and regulates DNA repair by the modification of 
post-translated proteins in response to cell signaling (Herceg & Wang, 2001). Cleaved 
caspase 3 inactivates PARP by cleavage as cleaved PARP inhibits the repair of DNA 
(Ouyang et al., 2012). Cleaved caspase 3 additionally activates proteases to degrade 
nuclear or cytoskeletal proteins or cytoplasmic endonucleases to degrade nuclear material 
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(Elmore, 2007). This allows for the final execution of apoptosis and morphological 
alterations.  
The morphological alterations of the apoptotic process, described by Kerr, Wylie & Currie 
(1972), include shrinkage of cells in response to organelles becoming more tightly packaged 
and cytoplasm density changes. Nuclear condensation and the cleavage of chromosomal 
DNA into internucleosomal fragments is also observed (Renehan, Booth & Potten, 2001). 
The loss of cell-cell adhesion and ECM adhesion produces dynamic membrane blebbing. 
Due to these morphological changes, apoptotic bodies are formed that are degraded by non-
inflammatory phagocytosis (Kerr, Wylie & Currie, 1972). The content of apoptotic bodies is 
dependent on cellular components that were located in areas where membranes underwent 
bledding.  
 
1.5.4. Cancer and apoptosis 
Mutations in the proliferation signaling of breast cells, such as increased expression of 
PI3K/Akt proteins and ERK proteins, promote cell survival gene expression as well as inhibit 
apoptosis (Weinstein-Oppenheimer et al., 2001). This prevents damaged cells from being 
effectively removed, promoting cancer development and progression. Cell death avoidance, 
such as evasion of apoptosis, is a hallmark of cancer (Hanahan & Weinberg, 2011). Cancer 
cells display dysregulation of Bcl-2 proteins, such as an increase in anti-apoptotic Bcl-2 
proteins or decrease in pro-apoptotic Bad protein, result in suppression of apoptosis which 
may lead to drug resistance (Kerr, Wylie & Currie, 1972). Chemotherapeutic agents, such as 
DXR, induce DNA damage and ROS to promote apoptotic cell death in cancer cells (Elmore, 
2007). Additionally, DXR was observed to influence the apoptotic pathway through Bcl-2/Bax 
interactions (Leung & Wang, 1999). The concentration and treatment period of 
chemotherapeutic drugs to regulate this ratio therefore require to be optimized. The 
stimulation of the extrinsic apoptotic pathway by DXR has also been observed (Reed, 1994).  
 
 
1.6. Invasion and Metastasis 
The local occupation of tissue that is not the origin tissue of cancer cells is known as 
invasion while the occupation of distant organs by the cancer cells is known as metastasis 
(Mareel & Constantino, 2011). Surgery, endocrine therapy, radiotherapy or chemotherapy 
may stimulate signaling pathways in a tumour that promote invasion and metastasis (Ceelen 
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& Bracke, 2009; Mareel & Constantino, 2011). Invasion and metastasis are hallmarks of 
cancer and have been associated with the increase in therapy resistance and poor patient 
prognosis (Hanahan & Weinberg, 2011). Invasion and metastasis are multistep processes 
involving a large variety of cellular programs such as proliferation, cell-cell adhesion, cell-
matrix adhesion, proteolysis, migration, and cell survival through the avoidance of cell death 
(Mareel & Constantino, 2011). The interactions occur between clusters of the same and 
different cell types, activation of several signaling pathways, and involves various sites within 
the body. 
Bidard et al. (2008) described one possible mechanism of metastasis that occurs in three 
processes. Firstly, cells collectively migrate through the ECM, due to EMT activation, 
allowing the formation of gaps in the ECM. The migration of these initial cells may influence 
the direction and degree of metastasis. Secondly, there is a release of non-metastatic 
cancer cells, which have not undergone EMT, by the tumour into circulation by using the 
pathway formed by the initial invading cells. In combination with the initial cells, clusters of 
cells are formed and microenvironmental changes are made in the endothelium of the 
potential metastatic site. This develops a pre-metastatic niche. Finally, after the development 
of the pre-metastatic niche, circulating cells from the primary tumour populate and further 
alter the microenvironment of the secondary site to form final secondary tumours.  
Tsuji, Ibaragi & Hu (2009) however proposed an alternative process in the mechanism of 
metastasis described by Bidard et al. (2008).  They suggested that following invasion of 
EMT activated cancer cells into circulation these cells become dormant. The non-EMT 
cancer cells released into circulation are therefore solely responsible for adhesion to the 
endothelium of the secondary tumour site. These non-EMT cells alone are responsible for 
the development of the pre-metastatic niche and development of secondary tumours. This 
theory allowed for the elucidation of epithelial, E-cadherin positive phenotypes in these 
secondary tumours. Both the theories of Bidard et al. (2008) and Tsuji, Ibaragi & Hu (2009) 
highlighted the significant role that EMT has on the migration, invasion, and metastasis of 
cancer cells.  
 
1.6.1. Epithelial-Mesenchymal Transition 
The EMT is a highly conserved cellular process associated with one of the hallmarks and 
progression of cancer (Wong et al., 2018). Based on the biological context in which the EMT 
can be found, it can be classified into three subtypes. Type I occurs within embryogenesis 
and organ development, Type II occurs in fibrosis and wound healing while being associated 
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with inflammation, and the final Type III occurs in cancer and will be the focus of this section 
(Zeisberg & Nelson, 2009). During EMT, epithelial cells that are attached to the basement 
membrane undergo various biochemical alterations that cause them to exhibit a 
mesenchymal phenotype (Kalluri & Weinberg, 2009). The mesenchymal phenotype 
promotes apoptotic resistance, cell migration, ECM component alterations as well as 
invasion and metastasis (Singh & Settleman, 2010). Apoptotic resistance as a result of EMT 
has also been observed to encourage drug resistance in cancer cells (Housman et al., 
2014). The plasticity of the EMT means that this process can be reversed with 
mesenchymal-epithelial-transition (MET) though little information is known about MET 
(Kalluri & Neilson, 2003). It has been shown that cancer cells which have undergone EMT 
and migrated to form secondary tumours at distant sites, do not maintain their mesenchymal 
phenotype (Zeisberg, Shah & Kalluri, 2004).  The tumour at the secondary site is 
histopathologically similar to the primary tumour. The dissemination of secondary tumour 
cells to undergo MET is predicted to be due to the absence of signals in the primary tumour 
that induced EMT (Thiery, 2002). 
During EMT various components are either induced or inhibited (Figure 1.8). These include 
reorganization and altered expression of the cytoskeletal proteins α-smooth muscle actin (α-
SMA) and vimentin, the activation of transcription factors SNAIL, SLUG and TWIST 
(Guarino, Rubino & Ballabio, 2007), decreased expression of the cell surface protein E-
cadherin as well as production of ECM-degrading enzymes and microRNA changes (Kalluri 
& Weinberg, 2009). Cancer cells that are the first to invade away from the primary tumour 
site have been found to express mesenchymal markers. These cells then enter into the 
invasion-metastasis cascade (Thiery, 2002). Although the mechanisms and signaling of 
EMT are not fully elucidated, molecules in the stroma associated with the tumour, such as 
hepatocyte growth factor (HGF), platelet-derived growth factor (PDGF), and TGF-β, induce 
EMT in two possible pathways. Smad proteins assisting the binding of TGF-β to activin 
receptor-like kinase-5 (ALK-5) receptor on the cell membrane induce motility activation. 
Autocine production of TGF-β is modulated by TGF-β and Smad that reinforces and up 
regulates EMT (Derynck, Akhurst & Balmain, 2001). Alternatively, significant evidence has 
indicated that TGF-β can induce EMT activation through the ERK pathway in mammary 
epithelial cells and hepatocytes (Kalluri & Weinberg, 2009; Zhang, Zhou & ten Dijke, 2013).  
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Figure 1.8: Markers of the Epithelial- Mesenchymal Transition (EMT) and Mesenchymal-
Epithelial Transition (MET) dynamic processes.  Increased expression of mesenchymal markers 
promotes a mesenchymal phenotype and the induction of Epithelial- Mesenchymal Transition (EMT) 
in epithelial cells while an increase expression of epithelial markers promotes an epithelial phenotype 
and the induction of Mesenchymal-Epithelial Transition (MET). Scheme reproduced from Hyun et al. 
(2016). 
 
1.6.2.  α-Smooth muscle actin 
The protein α-SMA provides mechanical tension generated by the cell in order to maintain 
cell structure and motility. It is responsible for cell structure, integrity, and serves as an 
important component of the contractile apparatus. Fibrogenesis and the epithelial 
mesenchymal transition are influenced by the expression of α-SMA in cells and surrounding 
environments (Lee et al., 2013). Due to the actin cytoskeleton influencing cell motility, 
alterations in actin expression promotes increased invasion and metastasis of cancer 
(Lambrechts, van Troys & Ampe, 2004). Lee et al. (2013) observed that EMT induction was 
influenced by α-SMA expression in lung adenocarcinoma. TGF-β was also observed to 
promote EMT in epithelial cancer cells that induces the expression of α-SMA (Masszi et al., 
2003). Smooth muscle cells and activated cancer-associated fibroblasts significantly express 
α-SMA, however, tumour cells are speculated to use actin bundles in order to invade 
surrounding tissue and metastases (Lambrechts, van Troys & Ampe, 2004).  
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1.6.3. Vimentin 
Vimentin is the major cytoskeletal structural protein in mescenchymal cells. It is a type III 
intermediate filament (IF) that forms part of the cytoskeleton in combination with tubulin 
microtubules and actin microfilaments (Satelli & Li, 2011). Vimentin is responsible for the 
integrity of the cytoplasm, maintaining cell shape and the stabilization of interactions in the 
cytoskeleton. Vimentin expression is found in a variety of cell types including skeletal muscle 
(Sarnat, 1992). The influence of vimentin expression on cancer progression has not been 
fully investigated, however, vimentin has been shown to mediate migration of breast cancer 
cells through Ras activation (Vuoriluoto et al., 2010). It has been shown that NF-κβ and 
TGF-β induction is important in the activation and maintenance of EMT as both these 
components bind to the promoter region of vimentin (Huber et al., 2004; Wu et al., 2007). E-
cadherin expression has been observed to correlate with the expression of vimentin 
(Sommers et al., 1994). Additionally, several aggressive breast cancer cell lines have been 
shown to exhibit increased expression of vimentin that correlated with increased migration 
and invasion (Gilles et al., 2003). The induction of EMT is not the only process mediated by 
vimentin expression in epithelial cells, the induction of the reverse process, MET has also 
been shown to be mediated by vimentin (Satelli & Li, 2011).  
 
1.6.4. SNAIL 
SNAIL is a transcription factor associated with the suppression of E-cadherin as well as with 
neural differentiation and cell survival (Wang et al., 2013). The family proteins of SNAIL 
include SNAIL 1 (SNAIL), SNAIL 2 (SLUG), and SNAIL 3 (SMUC), which are all 
transcriptional factors. These proteins consist of a highly conserved C-terminal domain that 
binds to the E-box motif (5’-CANNTG-3’) present within targeted gene promoters (Nieto, 
2002). The N-terminal consists of the conserved SNAG (SNAIL/Gfi) domain that is important 
for the binding of multiple transcriptional co-repressor complexes. Tumour grade, metastasis 
and poor patient prognosis have been found to positively correlate with SNAIL expression 
(Peinado, Olmeda & Cano, 2007; Chen et al., 2010). Once TGF-β expression is up 
regulated, TGF-β induces activation of the transcription factors SNAIL, SLUG, and survival 
of motor neuron protein interacting protein 1 (SIP1). The PI3K-Akt pathway alternatively 
induces downstream effects on growth factors that activate receptor tyrosine kinases 
(RTKs). This activation then induces SNAIL activity (Wang et al., 2013). Phosphorylation of 
NF-κβ, by Akt also up regulates SNAIL activity (Julien et al., 2007). 
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1.6.5. E-cadherin 
E-cadherin is a cell surface protein important for the formation and maintenance of adherent 
junctions within cell-cell adhesion. Within the mammary gland, E-cadherin is required for 
normal cell function of cells in the lactating gland (Boussadia et al., 2002). SNAIL mediates 
the methylation of the E-cadherin promoter with histone H3 lysine 9-methylation (H3K9me3) 
(Dong et al., 2012). The repressor binding to the promoter region induces epigenetic 
alterations consequently blocking transcriptional machineries from accessing the promoter. 
Alterations in E-cadherin expression have been associated with increased invasion and 
progression of tumours in breast (Li et al., 2017), ovarian (Sawada et al., 2008), prostate 
(Umbas et al., 1997), colorectal (Christou et al., 2017), and gastric cancer (Liu & Chu, 2014). 
The decrease of E-cadherin expression can be a consequence of the alterations of EMT or it 
can be directly influenced by the EMT, such as the significant upregulation of the 
transcription factor SNAIL (Hollestelle et al., 2013). Coding sequence mutations account for 
the minority of dysfunctional E-cadherin expression in cancer (Jeanes, Gottardi & Yap, 
2008), while epigenetic alterations at various positions of the promoter region play a 
significant role in expression dysregulation (Wong et al., 2018). Early studies reported that 
E-cadherin expression was an important contributor to the suppression of invasion and that 
the decrease in its expression induced invasion as well as dedifferentiated or poorly 
differentiated carcinomas (Wong et al., 2018). Contradictory, recent studies observed breast 
cancer metastases or metastatic tumours originating from these cells, to express elevated E-
cadherin expression and have induced the EMT (Chao, Shepard & Wells, 2010).  
 
1.6.6. Hybrid phenotypes 
The completion of EMT is characterized by the degradation of the epithelial basement 
membrane and the development of a mesenchymal phenotypic cell that is able to migrate to 
other locations, other than that of epithelium origin (Kalluri & Weinberg, 2009; Mareel & 
Constantino, 2011). Due to this, cancer cells were previously assumed to obtain fully 
epithelial or mesenchymal state following MET or EMT (Thiery, 2002). Current studies 
however have shown that these are not binary processes as cancer cells may consist of 
phenotypes that express both epithelial and mesenchymal markers (Jolly et al., 2017). 
Additionally, carcinoma cells have been shown to undergo partial transitions rather than a 
terminal epithelial or mesenchymal state (Lambert, Pattabiramn & Weinberg, 2017). This 
hybrid phenotype is significantly found more regularly in TNBC patients (Yu et al., 2013). 
Cancer cells with hybrid phenotypes are able to rapidly enter back into the cell cycle and 
proliferate after metastasis to secondary sites. Cancer cells that undergo EMT or MET and 
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express an epithelial, mesenchymal or hybrid phenotype will have different responses to 
signaling pathways for cell growth, cell death, metastasis and drug resistance.  
 
1.7. Skeletal Muscle 
The contractile and metabolic properties of muscle fiber types are influenced by systemic 
and local microenvironments and are favorably plastic (Schiaffino & Reggiani, 2011). The 
mitochondria are linked to the regulation of cellular processes involved in remodeling and 
growth within skeletal muscle (Hardee, Montalvo & Carson, 2017). The disruption of 
oxidative metabolism will decrease basal protein synthesis within skeletal muscle (Hardee, 
Montalvo & Carson, 2017). The mitochondrial content and metabolic enzyme capacities of 
different fiber types vary. This allows the rate and capacity of protein synthesis in oxidative 
muscles to be greater than glycolytic muscles (Habets et al., 1999). The human body 
consists of 50% skeletal muscle, however, cancer metastasis into skeletal muscle, including 
breast cancer, is uncommon (Surov et al., 2009). Breast cancer patients have reported a 
reduction in body mass, loss of muscle strength, and muscle fatigue that are intensified 
during chemotherapy (Fox et al., 2009; Klassen et al., 2016). 
 
1.7.1. Cancer Cachexia 
Skeletal mass depletion is a wasting syndrome referred to as cachexia (Hardee, Montalvo & 
Carson, 2017). Increased susceptibility to treatment-induced toxicity, reduced physical 
function and psychosocial ability reduction have been observed with the depletion of muscle 
mass (Jung et al., 2015). Cancer-induced cachectic muscles have interlinking processes 
that allow for interrupted muscle oxidative metabolism and protein turnover (Hardee, 
Montalvo & Carson, 2017). These small variations in daily protein synthesis induce a 
significant disruption in long-term skeletal muscle maintenance (Horstman et al., 2016). 
Stimuli in both systemic and local environments induce a response in skeletal muscles that 
disturb the energy metabolism and proteostasis (Carson, Hardee & VanderVeen, 2016). 
These stimuli may be directly secreted from the cancer or be downstream stimuli from other 
mechanisms influenced by the cancer. Anabolic resistance is a term used to describe the 
inability to stimulate protein synthesis and plays a significant role in the regulation of muscle 
mass loss with aging (Fry & Rasmussen, 2011). The suppression of basal protein synthesis 
in cancer patients and preclinical cachexia models has been observed and attributed to 
muscle wasting (Dworzak et al., 1998).  
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Wasting susceptibility is influenced by the oxidative metabolism capacity of skeletal muscles. 
Models of cancer cachexia demonstrated that mitochondrial dysfunction influences 
metabolic and energetic stress pathways that regulate protein synthesis (Hardee, Montalvo 
& Carson, 2017). The loss of skeletal muscle mass was directly associated with the 
morbidity and mortality of cancer patients as cachexia is credited to be the cause of death of 
20-40% of cancer patients (Tisdale, 2009). In breast cancer patients however, a decrease in 
body weight and muscle mass was observed in only 24% of patients, while patients with 
gastric and pancreatic cancer experienced greater weight loss (Fox et al., 2009). 
Mitochondrial dysfunction in skeletal muscle, due to tumour growth, has been observed 
indicating communication between the skeletal muscle microenvironment and cancer 
microenvironment (Tzika et al., 2013). DXR treatment was shown to reduce muscle mass in 
cancer patients by targeting type 1 and type 2 fibers (Tozer et al., 2008). The mechanism by 
which DXR is able to induce catabolism in muscles is currently undefined however, the 
production of ROS is shown to be significant in the process (Gilliam et al., 2011). In both 
skeletal and cardiac muscle, the ROS produced by DXR targets the complexes of the 
mitochondrial ETC (Min et al., 2015). This results in muscle degradation by the activation of 
downstream pathways such as apoptosis, through Caspase 3 activity, and the ubiquitin-
proteasome pathway (Jackman & Kandarian, 2004). A study completed by Bohlen et al. 
(2018) investigated the alterations in skeletal muscles of breast cancer patients. They 
observed that oxidative phosphorylation and mitochondrial pathways were dysfunctional in 
breast cancer patients that were not undergoing chemotherapeutic treatment as well as 
those that were. This was present within early stage breast cancer development of luminal, 
triple positive as well as triple negative breast cancer tumours. The activity of complexes in 
the mitochondrial ETC were down regulated as well as alterations in energy metabolism due 
to peroxisome proliferator-activated receptor (PPAR)-related signaling. The transcriptional 
alterations were not dependent on cancer type or treatment. The authors further speculated 
that cancer patients who experience significant weight and muscle loss undergo complete 
muscle atrophy while patients who experience minimum weight loss, such as breast cancer 
patients, exhibit dysregulation of oxidative phosphorylation pathways within skeletal muscle 
mitochondria (Bohlen et al., 2018). While the influence of breast cancer and DXR on skeletal 
muscle has been investigated, the impact of skeletal muscle and DXR induced skeletal 
muscle dysfunction on breast cancer remains unclear. Investigating and elucidating the 
mechanisms linking cachexia and cancer could improve the treatment outcome of cancer 
patients. 
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1.8. Problem Statement 
Although it is well established that cancer is a genetic disease, in the last decade our genetic 
view has expanded by the observation that tumours are thriving organs with multiple cell 
types which can affect tumour progression and response to therapy. This view has added 
significant complexity to the study of cancer when the effects of fibroblasts, mesothelial cells, 
immune cells, adipocytes, endothelial cells and muscle cells are taken into account. Since 
the pectoris muscle is in close proximity of the mammary gland, and chemotherapy also 
induces muscle wasting, it is important to investigate the interaction of skeletal muscle with 
cancer cells. The impact of the skeletal muscle microenvironment, in response to cancer and 
DXR treatment, on the efficiently of DXR to induce cell death in breast cancer cells has not 
been fully investigated. Understanding the mechanisms involved in the development of drug 
resistance and cancer metastasis is crucial to improve patient prognosis, especially since 
these two events have a significant impact on cancer mortality. 
 
 
1.9. Hypothesis 
We hypothesize that the skeletal muscle microenvironment of C2C12 myotubes will alter the 
response of E0771 breast cancer cells to DXR treatment resulting in increased resistance, 
promotion of proliferation, apoptosis avoidance, and metastasis induction.  
 
 
1.10. Aims 
1. To investigate the reciprocal interactions between mouse breast cancer cells (E0771) 
and mouse myotubes (C2C12). 
2. To investigate the effects of DXR on the interactions between mouse breast cancer cells 
(E0771) and mouse myotubes (C2C12). 
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1.11. Objectives 
• Determine the influence of E0771 conditioned media with/without DXR on mitochondrial 
oxidative stress and cell integrity in C2C12 myotubes. 
 
• Determine the effect of myotube conditioned media with/without DXR on drug resistance 
and proliferation pathways in E0771 cells. 
 
• Determine the effect of myotube conditioned media with/without DXR on the apoptotic 
pathway in E0771 cells. 
 
• Determine the effect of myotube conditioned media with/without DXR on migratory and 
metastatic pathways in E0771 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9: Scheme representing the reciprocal workflow for study. The investigation of the 
dynamic interacts between E0771 cells and myotubes consists of treatment cycles of conditioned 
media as represented. 
E0771 
Myotubes 
E0771 
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Chapter 2: Materials and Methods 
2.1. Cell Culture 
A mouse metastatic mammary carcinoma cell line, E0771, and a mouse skeletal muscle cell 
line, C2C12, were used in this study. Cell lines were cultured in sterile Dulbecco’s Modified 
Eagle’s Medium (DMEM) (Gibco®, ThermoFisher Scientific®, #41965-062) supplemented 
with filtered 10% fetal bovine serum (FBS) (Capricorn Scientific®, ThermoFisher Scientific®, 
#FBS-G1-12A) and 1% Penicillin-Streptomycin (Gibco®, ThermoFisher Scientific®, #15140-
122). Cells were incubated at 37oC and 5% CO2 throughout the study. Cells were sub-
cultured regularly once 70 – 80% confluency was achieved with the aid of 0.25% Trypsin-
EDTA (Gibco®, ThermoFisher Scientific®, #25200072) followed by cell counting.  E0771 
cells were seeded, as required, at a density of 25 000 cells per well in a 96-well plate, 50 
000 cells per well in a 24-well plate and 250 000 cells per well in a 6-well plate. The C2C12 
cells were seeded at a density of 800 000 cells per T25 flask, and 50 000 cells in a 24-well 
plate. The C2C12 cells were allowed to grow to 70% confluency before being differentiated 
with 1% Horse Serum (Lonza, BioWhittaker®, #14-403F) for four days to induce myotube 
formation. After differentiation, media was removed and treatments commenced. Complete 
cell culture protocols for both E0771 cells and C2C12 cells can be found in Appendix D. For 
each experiment, the treatments for E0771 and C2C12 cell lines occurred in triplicate for a 
24-hour time period. Each experiment was individually repeated three times in order to 
establish an n = 3. 
 
2.2. Conditioned Media 
Two individual treatment cycles of conditioned media were collected. The first cycle of 
conditioned media was collected from E0771 cells after a 24-hour treatment. Conditioned 
media was then centrifuged at 10 000 rpm for 10 minutes at 4°C. Media was finally filtered 
with a 0.2 micron syringe filter (Lasec®, #FLAS25AC2050) before being snap frozen in liquid 
nitrogen and stored at -80°C until use. The collection of the second cycle of conditioned 
media was collected from myotubes after a 24-hour treatment period. This conditioned 
media was harvested, purified and stored as the E0771 cells previously described. 
 
2.3. Treatments 
Treatment groups for the production of the first cycle of conditioned media from the E0771 
cells included a Control group consisting only of serum free media (SFM) and a doxorubicin 
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(DXR) group consisting of SFM and DXR as seen at the top of Figure 2.1. DXR was 
prepared in DMSO as a stock solution of 3.4 µM (Lasec®, #FLAS25AC2050) before being 
added to SFM to obtain a final concentration of 1.6 µM. 
The treatment for the second cycle of conditioned media to be harvested and for all myotube 
experiments indicated in the middle section of Figure 2.1. These treatments consisted of a 
control group (Control) containing 50% SFM and 50% differentiation media, a DXR group 
(DXR) containing 50% SFM, 50% differentiation media and 1.6 µM DXR, a conditioned 
media control group (C.Control) containing 50% SFM and 50% control conditioned media 
from E0771 cells, and a conditioned media DXR group (C.DXR) containing 50% SFM and 
50% DXR conditioned media from E0771 cells. 
Figure 2.1: A visual representation of 24-hour treatments for the production of conditioned media and 
experiments on myotubes and E0771 cells. All treatments were prepared in a 1:1 ratio with serum free media 
and the relevant complete media or conditioned media. For both cell lines, Control consisted of serum free media 
and complete media while DXR consisted of serum free media, complete media and 1.6 µM. Myotube 
conditioned media treatments for experiments contained conditioned media harvested from Control and DXR 
treated E0771 cells. The conditioned media treatment of E0771 cells for experiments contained conditioned 
media harvested from Control and DXR treated myotubes as well as myotubes treated with conditioned media 
from E0771 cells. 
 
 
Treatment of the E0771 cells for all experiments is indicated at the bottom of Figure 2.1. 
These treatment groups consisted of the following treatment groups: a control group 
(Control) containing only SFM, a DXR group (DXR) containing SFM and 1.6 µM DXR, a 
conditioned media control group (C.Control) containing 50% SFM and 50% control 
conditioned media from myotubes, a conditioned media DXR group (C.DXR) containing 50% 
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SFM and 50% DXR conditioned media from myotubes, an E0771 conditioned media control 
group (C.C.Control) containing 50% SFM and 50% control conditioned media from 
myotubes treated with E0771 conditioned media, and an E0771 conditioned media DXR 
group (C.C.DXR) containing 50% SFM and 50% DXR conditioned media from myotubes 
treated with E0771 conditioned media. 
 
 
2.4. Assessment of Mitochondrial ROS Production (MitoSOX™) 
MitoSOX™ (Invitrogen™, #M36009) is a fluorogenic dye that is able to permeate cells and 
target mitochondria. It is rapidly oxidized by super-oxide but no other reactive oxygen 
species. After the 24-hour treatment period of the myotubes, media was removed and cells 
washed with warm PBS (phosphate-buffered saline). A 5 µM MitoSOX™ working solution 
was prepared by dissolving the powder in PBS and 1% horse serum. The working solution 
was added to each well and allowed to incubate, covered in foil, under growth conditions for 
15 minutes. Afterwards, MitoSOX™ solution was carefully removed, cells washed with warm 
PBS and a 5 µM Hoechst 33342 (Sigma-Aldrich®, #B2261) working solution, prepared with 
serum free media, was added to each well. The cells in the plate were incubated covered 
again under growth conditions for 10 minutes before being washed with warm PBS. A 4% 
paraformaldehyde solution was then used to fix cells for 10 minutes followed by another 
wash with PBS. Dako fluorescent mounting media was added to each well for improved 
imaging. A Nikon Eclipse E400 microscope equipped with DS-Fi2 colour digital camera with 
DAPI barrier filter (excitation 340-380 nm, emission 435-483 nm) and Tx Red barrier filter 
(excitation 540-580 nm, emission 600-650 nm) was used to capture 6 random fields for 
imaging at 10X objective. Processing and analyses of images were completed using Fiji 
software (Schindelin et al., 2012) to determine florescent intensity as an indicator of 
mitochondria super-oxide production and mitochondrial function. 
 
2.5. Assessment of myotube width (Cell Tracker™) 
Myotubes are multi-nuclei cells and have high mitochondrial respiratory rates; therefore 
determining cell viability using a mitochondrial reductive assay, such as MTT, is inaccurate. 
Instead the viability and integrity of myotubes were determined based on alterations in 
myotube width and length, as a decrease in width indicates the presence of skeletal muscle 
catabolism (Gilliam et al., 2012). Cell tracker™ Green, CMFDA (5-chloromethylfluorescein 
diacetate) (Invitrogen™, #C2925), is a fluorescent dye used to indicate cell location. The dye 
is able to permeate cell membranes where it is then transformed into cell membrane- 
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insoluble reaction products. C2C12 cells were grown, differentiated and treated in 24-well 
plates. After the 24-hour treatment period, media was removed and cells were washed with 
warm PBS. Warm Cell tracker™ working solution was prepared by dissolving the powder in 
serum free media to a final concentration of 5 µM, before being added to each well and 
allowed to incubate covered in foil under growth conditions for 30 minutes. A 5 µM Hoechst 
33342 working solution, prepared in serum free media, was added to each well and allowed 
to incubate under growth conditions for another 10 minutes. The solution was removed and 
wells carefully washed with warm PBS. Fixation of cells was completed using 4% 
paraformaldehyde for 10 minutes followed by another wash with PBS. Dako fluorescent 
mounting media (Diagnostech®, #S302380) was added to each well for improved imaging. A 
Nikon Eclipse E400 microscope equipped with DS-Fi2 colour digital camera (Nikon, Japan) 
with DAPI barrier filter (excitation 340-380 nm, emission 435-483 nm) and FITC barrier filter 
(excitation 465-495 nm, emission 515-555 nm) was used to capture 6 random fields for 
imaging with the 10X objective. Images were processed and analysis completed using Fiji 
software (Schindelin et al., 2012) to determine myotube width. 
 
2.6. Cell Viability Assessment 
A 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazoliumbromide (MTT) cell viability assay was 
conducted to assess mitochondrial reductive capacity, as an indication of the percentage of 
viable cells after treatments (Riss et al., 2004). The MTT powder and solution is light 
sensitive therefore it was covered and the lights were switched off in the working area. The 
MTT solution was prepared by dissolving MTT powder (Sigma-Aldrich®, #M2003) in PBS to 
a final concentration of 0.01 g/mL. Additional PBS was added to a final ratio of 1:3 (0.01 
g/mL MTT:PBS) and mixed thoroughly. After the 24-hour treatment period, E0771 cells 
grown in 96-well plates were treated with MTT solution before being covered in foil and 
incubated for 1 hour under growth conditions. Viable respiring cells take up the yellow 
tetrazolium salt, present in the MTT solution, and produce purple formazan crystals. The 
crystals were then dissolved in an acidic Isopropanol/Triton-X 50:1 ratio solution and 
absorbance values read using a plate reader (EL 800 Universal Microplate Reader, Bio-Tek 
Instruments Inc) at 595 nm. Blank absorbance values were used to standardize treatment 
values and all values were analyzed as a percentage of the control. 
 
2.7. Migration Scratch Assay 
A migration scratch assay, also known as a wound-healing assay, was used to assess the 
migratory capacity of the E0771 cells. The E0771 cells were grown to 90-95% confluency in 
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a 6-well plate. Three individual scratch wounds were made using a sterile yellow pipette tip 
in each well. Cells were washed with warm sterile PBS to remove cellular debri before fresh 
growth media was added to each well. Due to the light sensitivity of DXR and Mitomycin C 
(MMC), treatment was completed after the initial images were acquired in order to prevent 
degrading of these products during initial set up. Brightfield images were acquired using the 
4X objective on an Olympus® IX81 inverted fluorescence microscope with the Olympus® 
Cell^R software (Olympus®, GMBH Japan). This microscope allows for live cell imaging as it 
is equipped with an incubator system that is temperature-controlled at 37°C. The X, Y and Z 
coordinates of each image position can be saved onto the system and accessed at the 
different time points, this allows for improved accuracy. Three random positions, on three 
different scratches, were saved and imaged per group, while the experiment was also 
repeated three times. Once the 0 hour time point images for all treatment groups were 
completed, the cells were refreshed with the required treatment, indicated in Figure 2.1, and 
10 µg/mL MMC (Sigma-Aldrich®, #M4287) dissolved in Dimethyl sulfoxide (DMSO) (Sigma-
Aldrich®, #D2650). Cells were treated with the cytostatic agent MMC in combination with the 
treatments, as this compound is a strong DNA cross linker and inhibits the synthesis of DNA. 
This allowed for the exclusion of cellular proliferation during wound closure. A dose 
response of MMC on E0771 cells was completed by Mitchell (2017), which indicated the 
optimal concentration of MMC to be 10 µg/mL. Additional images were taken at time points 
of 6, 12 and 24 hours at the same positions saved at time point 0. Analysis of each image 
was completed by measuring the area (µm2) of the wound (Justus et al, 2014), using Fiji 
software (Schindelin et al., 2012). Wound closure over time was determined using the 
equations in Figure 2.2 adapted from Davis (2016) and Mitchell (2017). 
 
% 𝑤𝑜𝑢𝑛𝑑 𝑐𝑙𝑜𝑠𝑢𝑟𝑒 𝑎𝑡 𝑥 ℎ𝑜𝑢𝑟 = 𝑊𝑜𝑢𝑛𝑑 𝑎𝑟𝑒𝑎 𝑎𝑡 0 ℎ𝑜𝑢𝑟 −𝑊𝑜𝑢𝑛𝑑 𝑎𝑟𝑒𝑎 𝑎𝑡 𝑥 ℎ𝑜𝑢𝑟𝑊𝑜𝑢𝑛𝑑 𝑎𝑟𝑒𝑎 𝑎𝑡 0 ℎ𝑜𝑢𝑟 ×100 
 𝑟𝑎𝑡𝑒 𝑜𝑓 𝑤𝑜𝑢𝑛𝑑 𝑐𝑙𝑜𝑠𝑢𝑟𝑒 𝑎𝑡 𝑥ℎ𝑜𝑢𝑟 %. ℎ𝑜𝑢𝑟!! = % 𝑤𝑜𝑢𝑛𝑑 𝑐𝑙𝑜𝑠𝑢𝑟𝑒 𝑥 ℎ𝑜𝑢𝑟𝑥  
 
Figure 2.2: Equations used for analyses of wound closure in migration scratch assay. Calculation of the 
percentage of wound closure over time and rate of wound closure using wound area measurement at timepoints 
following treatment of E0771 cells. Adapted from Davis (2016) and Mitchell (2017). 
 
 
Stellenbosch University  https://scholar.sun.ac.za
 37 
2.8. Protein Extraction 
Myotubes for protein extraction were grown, differentiated and treated in T25 flasks while 
E0771 cells were grown and treated in 6-well plates. Modified radioimmunoprecipitation 
(RIPA) buffer with pH 7.4 was prepared containing 65 mM Tris-base, 154 mM sodium 
chloride (NaCl), 1% nonyl phenoxypolyethoxylethanol (NP-40), 1% sodium deoxycholate, 5 
mM ethylenediamine tetraacetic acid (EDTA), 5 mM ethylene glycol-bis(β-aminoethyl ether)-
N,N,N’,N’-tetraacetic acid (EGTA), and 0.1% sodium dodecyl sulfate (SDS). Protease 
inhibitor cocktail at 1X dilution in dH2O (Roche, #11893580001), 1 mM sodium 
orthovanadate (Na3VO4), 1 mM sodium fluoride (NaF) and 1 mM Phenylmethylsulfonyl 
Flouoride (PMSF) was added to RIPA buffer immediately before use. Media from cells was 
removed and flasks/wells were washed twice with ice-cold PBS before adding RIPA buffer to 
all flasks/wells. A cell scraper was used to scrape cells loose from flasks/wells and cell 
suspensions from triplicate flasks/wells of the same treatment group were pooled into pre-
cooled microtubes. Sample lysates were kept on ice and sonicated (Sonicator S-4000, 
Ultrasonic Liquid Processors, Misonix) at amplitude of 5A for 5 seconds. Sonicated lysates 
were placed on ice to allow the foam to settle before being centrifuged at 16.3 g for 2 
minutes at 4oC. The supernatant was then collected in a clean-labeled pre-cooled centrifuge 
tube and kept on ice before being used for protein determination. 
 
2.9. Protein Determination & Sample Preparation 
The Bradford assay (Bradford, 1976) was used to determine the total quantity of protein 
within each lysate to ensure that equal amounts of protein were loaded into each well for 
electrophoresis. A bovine serum albumin (BSA) (Roche, #10735078001) working solution 
with a final concentration of 200 µg/mL was used to prepare standards on ice (0 µg/mL, 2 
µg/mL, 4 µg/mL, 8 µg/mL, 12 µg/mL, 16 µg/mL, and 20 µg/mL) in duplicate in order to 
establish a standard curve. The Bradford working solution containing Coomassie Brilliant 
Blue G-250 (Sigma-Aldrich®, #27815-25G), ethanol, phosphoric acid and dH2O was used at 
a ratio of 9:1 with the standards as well as in the sample lysates. A Cecil CE 2021 (2000 
Series) spectrophotometer, set to 595 nm and zeroed using a blank, was used to measure 
the absorbance of the standards and sample lysates. A standard curve was drawn in 
Microsoft® Excel and the protein concentration for each sample lysate was determined. 
While working on ice, the appropriate volumes of protein sample from each treatment group 
was added to the appropriate volume of Laemmil’s sample buffer, with a final concentration 
of 62.5 mM Tris with pH 6.8, 4% SDS, 10% glycerol, 0.03% Bromophenol blue, and 5% β-
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mercaptoethanol, as determined in the Bradford Assay. Prepared samples were mixed 
thoroughly and stored in the -80oC freezer until use. 
 
2.10. SDS-PAGE & Western blot 
Separations of protein samples were done with sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE). Stain free self-cast gels were prepared using 12% resolving 
solution, supplemented with 1% Trichloroethylene (TCE) (Sigma-Aldrich®, # T54801), and 
4% stacking solution. TCE binds to proteins and emits a fluorescent signal after activation 
using ultraviolet (UV) light allowing proteins to be visible without the requirement of a 
staining step, therefore stain free. Prepared samples were thawed on ice before being briefly 
vortexed, heated at 95oC for 5 minutes and kept on ice. BLUeye Prestained Protein Ladder 
(GeneDirex®, #PM007-0500) was loaded into first well of all gels in order to determine the 
molecular weights of specific bands. A standard sample was then loaded followed by the 
required protein samples. Proteins were separated at 90 V for 10 minutes until samples had 
passed through the stacking gel followed by separation at 100 V until completion. Gels were 
activated using the stain-free gel protocol: 2.5 minutes activation and 5-second exposure 
using the ChemiDoc™ MP Imaging System with Image Lab™ Software (Bio-Rad®). 
Proteins were transferred from the gel onto polyvinylidene fluoride (PVDF) membranes using 
the Bio-Rad® RTA Midi PVDF Transfer Kit (Bio-Rad®, #1704273), the TransBlot® Turbo™ 
Transfer System (Bio-Rad®) and the mixed molecular weight protocol for 7 minutes. PVDF 
membranes were washed with Tris-buffered saline and Tween-20 (Sigma-Aldrich®, #P1379) 
(TBS-T) before being blocked using a solution of 5% fat free milk or 5% BSA for 2-hours. 
Membranes were washed and incubated in the required primary antibody solution and 
incubated for 36-hours at 4oC. The complete list of antibodies given can be found in 
Appendix C. Once incubation was completed, membranes were washed before incubated 
in secondary antibodies at room temperature for 1 hour. PDVF membranes were developed 
using the Bio-Rad ChemiDoc™ MR Imaging system with Image Lab™ Software after the 
enhanced chemiluminescence (ECL) western blotting substrate (Bio-Rad®, #1705061) was 
applied. ECL is light sensitive therefore all lights in work area were switched off with ECL 
remaining covered during use. Normalization of protein loading was achieved by using the 
total protein content of each lane and a protein standard on Image Lab™ Version 7 Software 
for Mac®. Protein expression in visualized bands on membranes was expressed as a 
percentage (%) of control. 
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2.11. Statistical analyses 
Statistical analyses of data were performed with the use of GraphPad Prism® Version 5 for 
Windows® (GraphPad Software, San Diego, CA). All values represent percentage of control 
for mean ± standard error of mean. One-way ANOVA was performed with a Fisher’s least 
significant difference (LSD) post-hoc test. A p-value <0.05 was considered as statistically 
significant. All treatments were completed in triplicate and each experiment was repeated 
three times resulting in an n = 3. 
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Chapter 3 – Results I 
Introduction 
The muscle wasting syndrome, cachexia, is stimulated by stimuli from cancer cells or 
tumours as well as treatment-induced toxicity (Hardee, Montalvo & Carson. 2017). 
Mitochondrial dysfunction of skeletal muscle is also a result of tumour growth (Tzika et al., 
2013). In this chapter, the results are shown where the effects of DXR and E0771 
conditioned media on mitochondrial ROS production in myotubes were investigated. These 
experiments were done to ensure that a cachexia phenotype was introduced in the 
myotubes. A mouse breast adenocarcinoma cell line, E0771, and mouse myoblast cell line, 
C2C12, were chosen for this study as the cell lines are syngeneic to one another. DXR is the 
chemotherapeutic agent regularly used in South Africa for the treatment of various cancers 
including breast cancer and was used as our treatment of interest. Previous studies within 
our research group by determined that a dose of 1.6 µM (IC50 value) DXR induced ±50% 
cell death compared to control in E0771 cells. Conditioned media used to treat myotubes 
was harvested from E0771 cells after Control and DXR treatments, as previously described 
in chapter 3.3, and are indicated as C.Control and C.DXR. 
 
3.1. Induction of oxidative stress in myotubes 
Breast cancer has been observed to induce mitochondrial dysfunction and increase ROS 
production in skeletal muscle independent of chemotherapy (Bohlen et al., 2018). 
Additionally, DXR has a high affinity for components associated with the mitochondria and 
the complexes of the ETC that promote ROS production (Gilliam et al., 2012). In order to 
investigate ROS production in myotubes a MitoSOX™ assay was performed.  
 
3.1.1. Assessment of Mitochondrial ROS Production (MitoSOX™) 
Mitochondrial superoxide oxidizes MitoSOX™ within cells to produce a fluorescent signal. 
Alterations in fluorescent signal indicate changes in mitochondrial superoxide within the cells 
as observed in representational images of Figure 3.1. The auto-fluorescence signal of DXR 
was accounted and adjusted for in results presented in Figure 3.2. 
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Figure 3.1: Representative images of MitoSOX™ assay after 24-hour treatment of myotubes. Myotubes 
were treated for 24-hours with the following treatments: 1) Control consisting of serum free media and complete 
media in 1:1 ratio. 2) C.Control consisting of serum free media and conditioned media harvested from E0771 
cells after Control treatment in 1:1 ratio. 3) DXR consisting of serum free media and complete media in 1:1 ratio, 
and 1.6 µM DXR. 4) C.DXR consisting of serum free media and conditioned media harvested from E0771 cells 
after DXR treatment in 1:1 ratio. Tx Red filter indicates MitoSOX™, DAPI blue filter indicates nuclear DNA with 
Hoechst 33342, and combinational image indicates MitoSOX™ and Hoechst 33342. Images acquired with 40X 
objective. Scale = 200 µm. 
 
The mean fluorescent intensity (Figure 3.2) of C.Control exhibited no difference when 
compared to Control (4.285 ± 0.086 and 4.101 ± 0.152 respectively). The intensity of 
mitochondrial ROS significantly increased in DXR when compared to Control (5.580 ± 0.4, 
p<0.001) indicating DXR did promote ROS production. Additionally, while the intensity in 
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C.DXR (4.812 ± 0.122) exhibited no significant differences compared to C.Control, there was 
a significant increase of p<0.05 compared to Control, however, the mitochondrial ROS 
production was significantly lower compared to DXR (p<0.05). 
 
 
Figure 3.2: Mitochondrial ROS analysis from MitoSOX™ assay after 24-hour treatment of myotubes. 
Myotubes were treated for 24-hours with the following treatments: 1) Control consisting of serum free media and 
complete media in 1:1 ratio. 2) C.Control consisting of serum free media and conditioned media harvested from 
E0771 cells after Control treatment in 1:1 ratio. 3) DXR consisting of serum free media and complete media in 
1:1 ratio, and 1.6 µM DXR. 4) C.DXR consisting of serum free media and conditioned media harvested from 
E0771 cells after DXR treatment in 1:1 ratio. Values expressed as mean fluorescent intensity with statistical 
representation as mean ±SEM with n = 3. *p<0.05 compared to Control, ***p<0.001 compared to Control, 
#p<0.05 compared to DXR, ###p<0.001 compared to DXR. 
 
 
3.2. Maintenance of myotube integrity 
Minimal weight and muscle loss have been observed in breast cancer patients with cachexia 
and was reported to be associated with mitochondrial dysfunction of muscle and not 
complete muscle atrophy (Bohlen et al., 2018). In order to determine whether concentration 
of DXR selected and E0771 conditioned media induced muscle atrophy, the integrity and 
morphology was observed using a Cell Tracker™ Assay and western blot analyses. Due to 
time constraints analysis of apoptotic and autophagic markers in myotubes could not be 
completely investigated, however, preliminary results can be found in Appendix A, Figures 
A-D. 
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3.2.1. Assessment of myotube width (Cell Tracker™) 
Cell Tracker™ produces insoluble products within the cytosol allowing the entire cell to be 
fluorescently stained (Figure 3.3). This enables the measuring of myotube width in µm2 to 
determine alterations in myotube morphology and integrity. 
 
Figure 3.3: Representative images of Cell Tracker™ assay after 24-hour treatment of myotubes. Myotubes 
were treated for 24-hours with the following treatments: 1) Control consisting of serum free media and complete 
media in 1:1 ratio. 2) C.Control consisting of serum free media and conditioned media harvested from E0771 
cells after Control treatment in 1:1 ratio. 3) DXR consisting of serum free media and complete media in 1:1 ratio, 
and 1.6 µM DXR. 4) C.DXR consisting of serum free media and conditioned media harvested from E0771 cells 
after DXR treatment in 1:1 ratio. FITC green filter indicates Cell Tracker™, DAPI blue filter indicates nuclear DNA 
with Hoescht.33342, and combinational image indicates Cell Tracker™ and Hoescht.33342. Images acquired 
with 40X objective. Scale = 200 µm. 
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Analysis of Cell Tracker™ Assay (Figure 3.4) indicated that no difference was observed in 
the myotube width (µm2) between Control (15.250 µm2 ± 1.024) and C.Control (15.740 µm2 
± 1.709) indicating no loss of muscle integrity. While a decrease was observed in DXR 
(13.185 µm2 ± 1.271) compared to Control and in C.DXR (13.340 µm2 ± 0.995) compared to 
C.Control this was not significant. Minimal loss of myotube width was therefore observed in 
response to treatments. 
 
 
Figure 3.4: Myotube width (µm2) analysis from Cell Tracker™ assay after 24-hour treatment of myotubes. 
Myotubes were treated for 24-hours with the following treatments: 1) Control consisting of serum free media and 
complete media in 1:1 ratio. 2) C.Control consisting of serum free media and conditioned media harvested from 
E0771 cells after Control treatment in 1:1 ratio. 3) DXR consisting of serum free media and complete media in 
1:1 ratio, and 1.6 µM DXR. 4) C.DXR consisting of serum free media and conditioned media harvested from 
E0771 cells after DXR treatment in 1:1 ratio. Values expressed as myotube width (µm2) with statistical 
representation as mean ±SEM with n = 3. 
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Chapter 4 – Results II 
Introduction 
The development and progression of breast cancer is a complex process involving various 
mutations and dysfunctional signaling pathways responsible for cell proliferation, cell growth, 
cell death, and differentiation. The release of cytokines and growth factors by skeletal 
muscle in response to stimuli from cancer cells, chemotherapy treatment, or a combination 
of both, may inhibit or induce signaling pathways in breast cancer cells. In this chapter we 
assessed the influence of DXR and myotube conditioned media on mechanisms associated 
with drug resistance, cell proliferation, apoptosis, and metastasis. As previously described in 
chapter 2.3, conditioned media used to treat E0771 cells was harvested from myotubes 
following basic Control and DXR treatments, indicated as C.Control and C.DXR, as well as 
treatment of myotubes with E0771 conditioned media, indicated as C.C.Control and 
C.C.DXR. 
 
4.1. Conditioned media induce resistance in E0771 cells 
Due to the induction of adaptive or survival responses in cancer cells following treatment, 
cancer cells can develop drug resistance. As previously stated, the appropriate dose of 1.6 
µM DXR was chosen over a 24-hour treatment period. Cell viability was firstly assessed to 
determine if the intervention of a myotube microenvironment promoted more effective cell 
death or increased drug resistance in breast cancer cells after DXR treatment. As the 
myotube condition media contains >25% differentiation media, which contains horse serum, 
an additional MTT assay was completed and can be found in Appendix A, Figure E. This 
ensured that an increase in cell viability was due to cytokines and growth factors excreted by 
the myotubes and not due to stimulation directly from horse serum. 
 
4.1.1. Cell Viability Assessment 
An increase in the mitochondrial reductive capacity of an MTT assay is correlated with cell 
proliferation and an increase in cell viability. Alternatively, a decrease of reductive capacity is 
correlated with cell death and a decrease in cell viability. When compared to Control (± 
1.689) in Figure 4.1, C.Control exhibited a significant increase of p<0.01 in mitochondrial 
reductive capacity (116.731% ± 5.374) while no difference was observed in C.C.Control 
(108.687% ± 5.819). Additionally, no difference was observed between C.Control and 
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C.C.Control. A significant decrease in reductive capacity to 60.354% was observed in DXR 
(± 1.237) when compared to Control (p<0.001) indicating a loss of viable cells.  
Alternatively, when compared to DXR in Figure 4.1, a significant increase of p<0.01 was 
observed in C.DXR (115.443% ± 3.02) and p<0.001 in C.C.DXR (121.743% ± 3.442). The 
mitochondrial reductive capacity of C.DXR and C.C.DXR exhibited no differences, however, 
a significant difference was observed when comparing C.C.Control and C.C.DXR (p<0.05). 
 
Figure 4.1: Mitochondrial reductive capacity assessed from MTT assay after 24-hour treatment of E0771 
cells as an indicator of cell viability. E0771 cells were treated for 24-hours with the following treatments: 1) 
Control consisting of serum free media and complete media in 1:1 ratio. 2) C.Control consisting of serum free 
media and conditioned media harvested from myotubes after Control treatment in 1:1 ratio. 3) C.C.Control 
consisting of serum free media and conditioned media harvested from myotubes after E0771 Control treatment in 
1:1 ratio. 4) DXR consisting of serum free media and complete media in 1:1 ratio, and 1.6 µM DXR. 5) C.DXR 
consisting of serum free media and conditioned media harvested from myotubes after DXR treatment in 1:1 ratio. 
6) C.C.DXR consisting of serum free media and conditioned media harvested from myotubes after E0771 DXR 
treatment in 1:1 ratio. Values expressed as percentage (%) of control with statistical representation as mean 
±SEM with n = 3. **p<0.01 compared to Control, ***p<0.001 compared to Control, ###p<0.001 compared to 
DXR, %p<0.05 compared to C.C.DXR. 
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4.2. The effect of conditioned media on markers of cell proliferation 
Cell proliferation is a complex process and various signaling pathways are involved in its 
regulation. Breast cancer cells display dysregulation in one or more of these pathways, 
which promote unsuppressed growth. The PI3K/Akt and ERK pathways play important roles 
in the cell proliferation and inhibition of apoptosis in cancer cells. To support the results 
obtained in the cell viability assay, the protein expression of a marker from each pathway, as 
well as a member of the MCM protein family, were determined by means of western blot 
experiments. 
 
4.2.1. PI3K/Akt Pathway 
Akt is a significant protein in the PI3K/Akt pathway. Once activated, Akt mediates 
downstream effects on multiple intracellular proteins that influence cell survival, cell 
proliferation, cell growth, cell migration as well as angiogenesis. Unfortunately, due to the 
poor quality of the antibody, phosphorylated Akt could not be analysed and a fold change in 
the phosphor-Akt and total Akt ratio could not be established. A decrease in total Akt 
expression in C.Control (81.159% ± 1.745) was observed while no difference in expression 
in C.C.Control (100.53% ± 4.307) was observed when compared to Control (±15.75) (Figure 
4.2). Akt expression was also decreased in DXR (77.568% ± 2.534) when compared to 
Control. When compared to DXR, no differences were observed in C.DXR (84.778% ± 
10.13) and C.C.DXR (65.554% ± 17.55). Additionally, C.C.DXR exhibited a significant 
decreased in Akt expression when compared to C.C.Control (p<0.05). 
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Figure 4.2: Protein expression of total Akt from western blot analysis after 24-hour treatment of E0771 
cells. E0771 cells were treated for 24-hours with the following treatments: 1) Control consisting of serum free 
media and complete media in 1:1 ratio. 2) C.Control consisting of serum free media and conditioned media 
harvested from myotubes after Control treatment in 1:1 ratio. 3) C.C.Control consisting of serum free media and 
conditioned media harvested from myotubes after E0771 Control treatment in 1:1 ratio. 4) DXR consisting of 
serum free media and complete media in 1:1 ratio, and 1.6 µM DXR. 5) C.DXR consisting of serum free media 
and conditioned media harvested from myotubes after DXR treatment in 1:1 ratio. 6) C.C.DXR consisting of 
serum free media and conditioned media harvested from myotubes after E0771 DXR treatment in 1:1 ratio. 
Values expressed as percentage (%) of control with statistical representation as mean ±SEM with n = 3.  *p<0.05 
compared to Control, %p<0.05 compared to C.C.DXR. 
 
4.2.2. ERK pathway 
ERK proteins are responsible for the activation and regulation of processes involved in 
meiosis, mitosis and cell survival and proliferation. A ratio comparing the expression of 
phospho-ERK 2 and Total ERK indicates the activation of this protein. An increase in the 
ratio represents an increase in the activation of ERK through phosphorylation. C.Control and 
C.C.Control exhibited an increase in fold change of phospho-ERK 2 over total ERK 2 in 
Figure 4.3 when compared to Control (1.406 ± 0.137 and 1.785 ± 0.181). Additionally, DXR 
exhibited a statistically significant fold change to 3.946 (± 0.520, p<0.001) when compared to 
Control. While the ratio’s in C.DXR and C.C.DXR was significantly decreased compared to 
DXR (1.710 ± 0.272, p<0.001 and 1.822 ± 0.176, p<0.001), there were no differences 
observed during comparison of C.Control and C.DXR or C.C.Control and C.C.DXR. 
Total Protein 
60 kDa 
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Figure 4.3: Ratio of protein expression of phospho-ERK2 / Total ERK2 from western blot analysis after 
24-hour treatment of E0771 cells. E0771 cells were treated for 24-hours with the following treatments: 1) 
Control consisting of serum free media and complete media in 1:1 ratio. 2) C.Control consisting of serum free 
media and conditioned media harvested from myotubes after Control treatment in 1:1 ratio. 3) C.C.Control 
consisting of serum free media and conditioned media harvested from myotubes after E0771 Control treatment in 
1:1 ratio. 4) DXR consisting of serum free media and complete media in 1:1 ratio, and 1.6 µM DXR. 5) C.DXR 
consisting of serum free media and conditioned media harvested from myotubes after DXR treatment in 1:1 ratio. 
6) C.C.DXR consisting of serum free media and conditioned media harvested from myotubes after E0771 DXR 
treatment in 1:1 ratio. Values expressed as percentage (%) of control with statistical representation as mean 
±SEM with n = 3.  ***p<0.001 compared to Control, ###p<0.001 compared to DXR. 
 
4.2.3. Mini-chromosome maintenance (MCM) proteins 
MCM2, a member of the MCM protein family, plays an important role in DNA replication by 
recruiting other essential proteins as well as the formation of replication forks and serves 
thus as a marker of cellular proliferation. An increase in the expression of MCM2 indicates 
an increase in proliferation activity. Comparison of MCM2 expression to Control (± 9.153) in 
Figure 4.4 exhibited no difference in C.Control (102.109% ± 9.047), DXR (110.711% ± 
7.145) or C.DXR (96.897% ± 8.494). A decrease in expression to 89.121% (± 2.028) was 
however observed in C.C.Control when compared to Control. The expression of MCM2 was 
Total ERK 
Total Protein 
Phospho-ERK 42 kDa &44 kDa 
42 kDa &44 kDa 
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significantly decreased in C.C.DXR (55.167% ± 14.64) when compared to DXR (p<0.01) and 
C.C.Control (p<0.01). 
 
Figure 4.4: Protein expression of MCM2 from western blot analysis after 24-hour treatment of E0771 cells. 
E0771 cells were treated for 24-hours with the following treatments: 1) Control consisting of serum free media 
and complete media in 1:1 ratio. 2) C.Control consisting of serum free media and conditioned media harvested 
from myotubes after Control treatment in 1:1 ratio. 3) C.C.Control consisting of serum free media and conditioned 
media harvested from myotubes after E0771 Control treatment in 1:1 ratio. 4) DXR consisting of serum free 
media and complete media in 1:1 ratio, and 1.6 µM DXR. 5) C.DXR consisting of serum free media and 
conditioned media harvested from myotubes after DXR treatment in 1:1 ratio. 6) C.C.DXR consisting of serum 
free media and conditioned media harvested from myotubes after E0771 DXR treatment in 1:1 ratio. Values 
expressed as percentage (%) of control with statistical representation as mean ±SEM with n = 3. **p<0.01 
compared to Control, ##p<0.01 compared to DXR, %p<0.05 compared to C.C.DXR, %%p<0.01 compared to 
C.C.DXR. 
 
4.3. The effect of conditioned media on apoptosis 
Effective treatment of cancer with DXR induces apoptosis (Tacar, Sriamornsak & Dass, 
2012), however as discussed, drug resistant cells are able to evade apoptosis. Intervention 
of microenvironments may directly or indirectly, with the use of previously mentioned 
signaling pathways, inhibited apoptosis from occurring (Weinstein-Oppenheimer et al., 
2001). To determine whether DXR was capable of inducing cell death in the context of the 
Total Protein 
102 kDa 
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myotube microenvironment, the protein expression of apoptotic markers caspase 3 and 
PARP was determined using western blot analysis. 
 
4.3.1. Caspase 3 
Within the apoptotic pathway, both the extrinsic and intrinsic pathways are involved in the 
activation of caspase 3. Cleavage of this protein executes the final steps in the apoptotic 
process allowing for programmed cell death. An increase in the fold change ratio of the 
expression of cleaved caspase 3 and total caspase 3 indicates induction of this proteins 
cleavage, therefore activation of Caspase 3 activity. This increased cleavage activity of 
Caspase 3 represents the induction of the execution pathway, which may induce 
downstream cell death effects. Cleaved caspase 3 and total caspase 3 fold change in 
Figure 4.5 exhibited no differences between Control (± 0.567), C. Control (1.521 ± 0.792), 
C.C.Control (1.367 ± 0.661), and DXR (1.761 ± 0.522). There was an increase in fold 
change observed in C.DXR (2.962 ± 1.109) compared to DXR and C.Control, however this 
was not significant. The ratio observed in C.C.DXR (0.993 ± 0.209) was non-significantly 
decreased compared to DXR and C.DXR, however, not when compared to C.C.Control. The 
large variation exhibited in the ratio change of cleaved and total Caspase 3 attributed to non-
significance being observed.  
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Figure 4.5: Ratio of protein expression of cleaved Caspase 3 / total Caspase 3 from western blot analysis 
after 24-hour treatment of E0771 cells. E0771 cells were treated for 24-hours with the following treatments: 1) 
Control consisting of serum free media and complete media in 1:1 ratio. 2) C.Control consisting of serum free 
media and conditioned media harvested from myotubes after Control treatment in 1:1 ratio. 3) C.C.Control 
consisting of serum free media and conditioned media harvested from myotubes after E0771 Control treatment in 
1:1 ratio. 4) DXR consisting of serum free media and complete media in 1:1 ratio, and 1.6 µM DXR. 5) C.DXR 
consisting of serum free media and conditioned media harvested from myotubes after DXR treatment in 1:1 ratio. 
6) C.C.DXR consisting of serum free media and conditioned media harvested from myotubes after E0771 DXR 
treatment in 1:1 ratio. Values expressed as percentage (%) of control with statistical representation as mean 
±SEM with n = 3. 
 
4.3.2. Poly ADP ribose polymerase (PARP) 
Poly ADP ribose polymerase (PARP) is a protein found in the nucleus of a cell, where it is 
able to detect alterations in single-strand DNA and promotes apoptosis, genomic stability or 
DNA repair. Cleavage of PARP by caspase 3 causes inactivation of PARP activity. The 
increase expression of cleaved PARP compared to total PARP, thus the increase in fold 
change ratio, indicates the inhibition of PARP and induction of apoptosis. The fold change 
ratio of cleaved and total PARP is shown in Figure 4.6. Comparison of Control (1.018 ± 
0.075), C.Control (1.038 ± 0.068), and C.C.Control (1.064 ± 0.091) exhibited no difference in 
fold change ratio. Compared to Control, a significant decrease was observed in DXR with 
Total Caspase 3 
Total Protein 
Cleaved Caspase 3 
35 kDa 
17 & 19 kDa 
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the ratio decreasing to 0.651 (± 0.027, p<0.01). The decrease of fold change ratio in C.DXR 
(0.662 ± 0.097) was significant compared to C.Control (p<0.01) while the decrease in 
C.C.DXR (0.456 ± 0.111) was significant when compared to C.C.Control (p<0.001). 
 
Figure 4.6: Ratio of protein expression of cleaved PARP / total PARP from western blot analysis after 24-
hour treatment of E0771 cells. E0771 cells were treated for 24-hours with the following treatments: 1) Control 
consisting of serum free media and complete media in 1:1 ratio. 2) C.Control consisting of serum free media and 
conditioned media harvested from myotubes after Control treatment in 1:1 ratio. 3) C.C.Control consisting of 
serum free media and conditioned media harvested from myotubes after E0771 Control treatment in 1:1 ratio. 4) 
DXR consisting of serum free media and complete media in 1:1 ratio, and 1.6 µM DXR. 5) C.DXR consisting of 
serum free media and conditioned media harvested from myotubes after DXR treatment in 1:1 ratio. 6) C.C.DXR 
consisting of serum free media and conditioned media harvested from myotubes after E0771 DXR treatment in 
1:1 ratio. Values expressed as percentage (%) of control with statistical representation as mean ±SEM with n = 3. 
*p<0.05 compared to Control, **p<0.01 compared to Control, ***p<0.001 compared to Control, ##p<0.01 
compared to DXR, $$p<0.01 compared to C.DXR. %%%p<0.001 compared to C.C.DXR. 
 
4.4. The effect of conditioned media on cell migration 
Chemotherapy and microenvironments have been shown to stimulate migration activity in 
cancer cells, therefore promoting invasion and metastatic properties (Ceelen & Bracke, 
2009; Mareel & Constantino, 2011). To investigate the influence of the myotube 
Total Protein 
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Cleaved PARP 89 kDa 
116 kDa 
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microenvironment on breast cancer cell migration, a migration scratch assay was completed 
by making a scratch within a monolayer of cells and monitoring cell migration into the 
scratch over a period of 24-hours. Representative images of the scratches are shown in 
Figure 4.7.  
Figure 4.7: Representative images of migration scratch assay over 24-hours of treatment of E0771 cells. 
E0771 cells were treated for 24-hours with the following treatments: 1) Control consisting of serum free media 
and complete media in 1:1 ratio. 2) C.Control consisting of serum free media and conditioned media harvested 
from myotubes after Control treatment in 1:1 ratio. 3) C.C.Control consisting of serum free media and conditioned 
media harvested from myotubes after E0771 Control treatment in 1:1 ratio. 4) DXR consisting of serum free 
media and complete media in 1:1 ratio, and 1.6 µM DXR. 5) C.DXR consisting of serum free media and 
conditioned media harvested from myotubes after DXR treatment in 1:1 ratio. 6) C.C.DXR consisting of serum 
free media and conditioned media harvested from myotubes after E0771 DXR treatment in 1:1 ratio. Images 
were captured at 0 Hour, 6 Hours, 12 Hours and 24 Hours in order to measure area of the wound. Images 
acquired with 40X objective. 
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4.4.1. Percentage (%) of wound closure 
The percentage (%) of wound closure at each time point was calculated relative to the initial 
scratch (Figure 4.8). Mitomycin C was used to inhibit cell proliferation, therefore wound 
closure was an indicator of wound closure due to only cell migration and not proliferation. 
After 6-hours of treatment, the lowest percentage of wound closure was observed in 
C.Control with 4.123% (± 0.629), which was significantly lower to C.C.Control (8.093 ± 
0.955, p<0.001) and C.DXR (p<0.001). The highest percentage of closure was observed in 
DXR with 9.628% (± 0.628), which was significantly higher compared to Control (6.212% ± 
0.471, p<0.01). A significant difference was also observed between C.Control and C.DXR 
(p<0.001) but not between C.C.Control and C.C.DXR. 
Percentage of wound closure at 12-hours of treatment was increased among all treatments. 
C.Control continued to exhibit the lowest percentage of wound closure that was significant 
compared to C.C.Control (14.631% ± 1.804, p<0.01). A significant difference was observed 
between DXR (14.59% ± 0.946) and Control (8.128% ± 0.875, p<0.001). Finally, a significant 
difference was observed between C.Control and C.DXR (13.04 ± 0.801, p<0.001). 
C.Control continued to have the lowest significant wound closure percentage (10.713%, ± 
0.896) after 24-hours of treatment. The difference was observed to be significant when 
compared to C.C.Control (14.985% ± 1.024, p<0.01). Compared to DXR (16.049% ± 1.11), a 
significant difference was observed in Control (12.009% ± 1.278, p<0.01). Additionally, 
C.Control and C.DXR (17.19 ± 0.758) observed a significant difference in percentage of 
wound closure (p<0.001). 
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Figure 4.8: Percentage wound closure from migration scratch assay analysis over 24-hours of treatment 
of E0771 cells. E0771 cells were treated for 24-hours with the following treatments: 1) Control consisting of 
serum free media and complete media in 1:1 ratio. 2) C.Control consisting of serum free media and conditioned 
media harvested from myotubes after Control treatment in 1:1 ratio. 3) C.C.Control consisting of serum free 
media and conditioned media harvested from myotubes after E0771 Control treatment in 1:1 ratio. 4) DXR 
consisting of serum free media and complete media in 1:1 ratio, and 1.6 µM DXR. 5) C.DXR consisting of serum 
free media and conditioned media harvested from myotubes after DXR treatment in 1:1 ratio. 6) C.C.DXR 
consisting of serum free media and conditioned media harvested from myotubes after E0771 DXR treatment in 
1:1 ratio. Values expressed as percentage (%) of wound closure over time with statistical representation as mean 
±SEM with n = 3. *p<0.05 compared to control, **p<0.01 compared to control, ***p<0.001 compared to control, 
###p<0.001 compared to DXR, ++p<0.01 compared to C.Control, +++p<0.001 compared to C.Control. 
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4.4.2. Rate of wound closure 
The rate of wound closure (%.hr-1) for each treatment in Figure 4.9 was calculated as a 
percentage over time for each time point. After 6-hours of treatment, the lowest rate of 
wound closure was observed with 0.628 %.hr-1 (± 0.098) in C.Control. This rate was 
significantly lower when compared to Control (1.035 ± 0.079, p<0.05) and C.C.Control 
(1.349 ± 0.159, p<0.001). The highest rate of closure was observed in DXR with 1.605 %.hr-1 
(± 0.105), which was significantly different when compared to Control (p<0.01) and C.Control 
(p<0.001). 
All treatments showed a decrease in the rate of wound closure at the 12-hour time point with 
C.Control continuing to have the lowest rate with 0.561 %.hr-1 (± 0.074) that was significant 
when compared to C.C.Control (1.000 %.hr1 ± 0.129, p<0.01). Compared to Control (0.677 
%.hr1 ± 0.073), the difference in wound closure rate was no longer significant compared to 
C.Control, however there was a significant difference compared to C.C.Control (1.000 %.hr1 
± 0.129, p<0.05) and DXR (1.216 %.hr1 ± 0.079, p<0.001). Additionally, a significant 
difference was observed between C.Control and C.DXR (1.319 ± 0.102, p<0.001). 
The rate of wound closure was observed to decrease further after 24-hours in all treatments. 
C.Control continued to exhibit the lowest rate with 0.446 %.hr1 (± 0.034) that was significant 
when compared to C.C.Control (0.624 %.hr1 ± 0.043, p<0.001). The difference in wound 
closure rate in Control was significant when compared to C.C.Control (p<0.05) and DXR 
(0.669 %.hr1 ± 0.046, p<0.01). The comparison between C.Control and C.DXR was also 
observed to be significant (p<0.001). 
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Figure 4.9: Rate wound closure (%.hr-1) from migration scratch assay analysis over 24-hours of treatment 
of E0771 cells. E0771 cells were treated for 24-hours with the following treatments: 1) Control consisting of 
serum free media and complete media in 1:1 ratio. 2) C.Control consisting of serum free media and conditioned 
media harvested from myotubes after Control treatment in 1:1 ratio. 3) C.C.Control consisting of serum free 
media and conditioned media harvested from myotubes after E0771 Control treatment in 1:1 ratio. 4) DXR 
consisting of serum free media and complete media in 1:1 ratio, and 1.6 µM DXR. 5) C.DXR consisting of serum 
free media and conditioned media harvested from myotubes after DXR treatment in 1:1 ratio. 6) C.C.DXR 
consisting of serum free media and conditioned media harvested from myotubes after E0771 DXR treatment in 
1:1 ratio. Values expressed as rate wound closure over time (%.hr-1) with statistical representation as mean 
±SEM with n = 3. *p<0.05 compared to control, **p<0.01 compared to control, ***p<0.001 compared to control, 
###p<0.001 compared to DXR, ++p<0.01 compared to C.Control, +++p<0.001 compared to C.Control. 
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4.5. The effect of conditioned media on markers of Epithelial-
Mesenchymal Transition (EMT) 
EMT is an important process in the normal development and remodeling of the mammary 
gland (Nelson et al., 2006; Kouros-Mehr & Werb, 2006). However, dysregulation of this 
process in breast cancer can also promote invasion of tumours into surrounding tissue. EMT 
is also important to maintaining skeletal muscle functions and integrity since they have a 
plastic phenotype. Western blot analyses of epithelial and mesenchymal markers were 
performed to investigate alterations in cancer cell phenotype due to the myotube 
microenvironment. Time constraints prevented the complete investigation of EMT 
expression alterations in the myotubes due to E0771 conditioned media, although 
preliminary results of cytoskeleton EMT markers are indicated in Appendix A, Figures F-G. 
 
4.5.1. α-Smooth muscle actin 
The protein α-Smooth muscle actin (α-SMA) is responsible for cell structure and integrity as 
well as being an important component of the contractile apparatus. It is regarded as a 
mesenchymal marker and its expression is expected to increase during EMT. The protein 
expression of α-SMA in Figure 4.10 showed a decrease in C.Control (65.038% ± 12.86) and 
a significant decrease in C.C.Control (53.607% ± 12.63, p<0.05) compared to Control (± 
20.82). Additionally, compared to Control, no difference in expression was observed in DXR 
(102.127% ± 19.58). C.DXR exhibited decreased expression (65.574% ± 7.699) compared 
to DXR with no difference when compared to C.Control. A significant decrease in expression 
was observed in C.C.DXR (35.889% ± 8.666, p<0.01) compared to DXR while no alteration 
of expression was observed between C.C.DXR and C.C.Control. 
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Figure 4.10: Protein expression of α-Smooth Muscle Actin from western blot analysis after 24-hour 
treatment of E0771 cells. E0771 cells were treated for 24-hours with the following treatments: 1) Control 
consisting of serum free media and complete media in 1:1 ratio. 2) C.Control consisting of serum free media and 
conditioned media harvested from myotubes after Control treatment in 1:1 ratio. 3) C.C.Control consisting of 
serum free media and conditioned media harvested from myotubes after E0771 Control treatment in 1:1 ratio. 4) 
DXR consisting of serum free media and complete media in 1:1 ratio, and 1.6 µM DXR. 5) C.DXR consisting of 
serum free media and conditioned media harvested from myotubes after DXR treatment in 1:1 ratio. 6) C.C.DXR 
consisting of serum free media and conditioned media harvested from myotubes after E0771 DXR treatment in 
1:1 ratio. Values expressed as percentage (%) of control with statistical representation as mean ±SEM with n = 3. 
*p<0.05 compared to Control, **p<0.01 compared to Control, #p<0.05 compared to DXR, ##p<0.01 compared to 
DXR. 
 
4.5.2. Vimentin 
Vimentin is a major cytoskeletal structural protein in mesenchymal cells responsible for the 
integrity of the cytoplasm, maintaining cell shape and the stabilization of interactions in the 
cytoskeleton. An increased expression of vimentin is observed during a mesenchymal state 
compared to an epithelial state. The protein expression of vimentin in C.Control and 
C.C.Control was observed to increase to 118.227% (± 5.585) and 118.723% (± 5.9), 
respectively, when compare to Control (± 13.32) (Figure 4.11) however, this was not 
significant. Comparison of C.Control and C.C.Control as well as Control and DXR (90.181% 
± 4.42) showed no difference in expression.  The expression of vimentin in C.DXR 
Total Protein 
42 kDa 
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(128.996% ± 13.75) was significantly increased when compared to DXR (p<0.05) with a 
slight increase observed when compared to C.Control. While C.C.DXR (115.44% ± 15.11) 
exhibited an increase in expression when compared to DXR, no difference was observed 
when compared to C.C.Control. 
 
Figure 4.11: Protein expression of Vimentin from western blot analysis after 24-hour treatment of E0771 
cells. E0771 cells were treated for 24-hours with the following treatments: 1) Control consisting of serum free 
media and complete media in 1:1 ratio. 2) C.Control consisting of serum free media and conditioned media 
harvested from myotubes after Control treatment in 1:1 ratio. 3) C.C.Control consisting of serum free media and 
conditioned media harvested from myotubes after E0771 Control treatment in 1:1 ratio. 4) DXR consisting of 
serum free media and complete media in 1:1 ratio, and 1.6 µM DXR. 5) C.DXR consisting of serum free media 
and conditioned media harvested from myotubes after DXR treatment in 1:1 ratio. 6) C.C.DXR consisting of 
serum free media and conditioned media harvested from myotubes after E0771 DXR treatment in 1:1 ratio. 
Values expressed as percentage (%) of control with statistical representation as mean ±SEM with n = 3. #p<0.05 
compared to DXR. 
 
4.5.3. SNAIL 
SNAIL is a transcription factor important in the regulation of EMT.  During EMT, increased 
SNAIL expression modulates the expression of several EMT markers, including E-cadherin. 
In Figure 4.12, no differences were observed between Control (± 11.96), C.Control 
(102.947% ± 12.69), C.DXR (102.524% ± 23.92), and C.C.DXR (104.461% ± 17.4). DXR 
Total Protein 
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exhibited a decrease in expression of SNAIL to 74.337% (± 17.05) compared to Control (± 
11.96) that was also decreased compared to C.DXR and C.C.DXR. SNAIL expression in 
C.C.Control was increased (129.219% ± 23.21) compared to Control and C.C.DXR. 
 
Figure 4.12: Protein expression of SNAIL from western blot analysis after 24-hour treatment of E0771 
cells. E0771 cells were treated for 24-hours with the following treatments: 1) Control consisting of serum free 
media and complete media in 1:1 ratio. 2) C.Control consisting of serum free media and conditioned media 
harvested from myotubes after Control treatment in 1:1 ratio. 3) C.C.Control consisting of serum free media and 
conditioned media harvested from myotubes after E0771 Control treatment in 1:1 ratio. 4) DXR consisting of 
serum free media and complete media in 1:1 ratio, and 1.6 µM DXR. 5) C.DXR consisting of serum free media 
and conditioned media harvested from myotubes after DXR treatment in 1:1 ratio. 6) C.C.DXR consisting of 
serum free media and conditioned media harvested from myotubes after E0771 DXR treatment in 1:1 ratio. 
Values expressed as percentage (%) of control with statistical representation as mean ±SEM with n = 3.  
 
4.5.4. E-cadherin 
E-cadherin is a cell surface protein important for the formation and maintenance of adherent 
junctions within cell-cell adhesion. The loss of expression indicates an increase of metastatic 
properties of the cell. The expression of E-cadherin represented in Figure 4.12 indicated the 
when compared to Control (± 19.03), an increase of expression in C.Control (199.903% ± 
78.84), C.Control (200.649% ± 14.9) and DXR (237.571% ± 85.82) was observed. The 
Total Protein 
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expression observed in C.DXR (112.349% ± 5.994) was less than DXR and C.Control while 
no difference was observed when comparing C.C.DXR (202.854% ± 72.29) to DXR or 
C.C.Control. Variation was observed in E-cadherin expression among treatments 
represented in Figure 4.13 preventing significant changes to be observed. 
 
Figure 4.13: Protein expression of E-cadherin from western blot analysis after 24-hour treatment of E0771 
cells. E0771 cells were treated for 24-hours with the following treatments: 1) Control consisting of serum free 
media and complete media in 1:1 ratio. 2) C.Control consisting of serum free media and conditioned media 
harvested from myotubes after Control treatment in 1:1 ratio. 3) C.C.Control consisting of serum free media and 
conditioned media harvested from myotubes after E0771 Control treatment in 1:1 ratio. 4) DXR consisting of 
serum free media and complete media in 1:1 ratio, and 1.6 µM DXR. 5) C.DXR consisting of serum free media 
and conditioned media harvested from myotubes after DXR treatment in 1:1 ratio. 6) C.C.DXR consisting of 
serum free media and conditioned media harvested from myotubes after E0771 DXR treatment in 1:1 ratio. 
Values expressed as percentage (%) of control with statistical representation as mean ±SEM with n = 3. 
  
116 kDa 
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Chapter 5 – Discussion 
Introduction 
Dysregulation of signaling pathways in breast cancer cells promotes cancer development 
and progression. Mutations and alterations in proliferation pathways promote infinite 
replication, abnormal cell growth, and avoidance of growth suppression while dysfunctional 
cell death mechanisms inhibit the effective removal of cancerous cells by the body (Hanahan 
& Weinberg, 2011). Invasion and metastasis of cancer cells is also upregulated by 
dysregulation of EMT. These mechanisms each play a role in the development of drug 
resistance and cancer metastasis. Complex cancer microenvironment has observed to be 
influenced by various other factors, cells and microenvironments (Howard & Lu, 2014). The 
absence of information regarding the reciprocal interactions between breast cancer cells and 
skeletal muscle could provide essential information regarding breast cancer progression. 
Chemotherapeutic treatment targets various cells, tissues, and organs of cancer patients 
each of which respond differently (Tacar, Sriamrnsak & Dass, 2012). Understanding these 
responses and the mechanisms involved improve patient prognosis and lower mortality rate 
by ensuring effective chemotherapeutic treatment and preventing metastasis. This chapter 
will discuss the impact of the skeletal muscle microenvironment, in response to breast 
cancer and DXR treatment, on the efficiently of DXR to induce cell death and reduce 
progression of breast cancer cells. 
 
5.1. Myotube Mitochondrial Oxidative Stress  
Investigation of mitochondrial ROS production in myotubes was done using the MitoSOX™ 
assay. There were no differences in mean fluorescent intensity between the Control group 
and the group treated with cancer conditioned media obtained from E0771 cells (C.Control) 
(Figure 3.2). Therefore in our study, factors released from the breast cancer 
microenvironment did not result in increased production of mitochondrial ROS in myotubes. 
Our results contradict the results of McLean, Moylan & Andrade (2014) who observed that 
treatment of C2C12 myotubes with conditioned media harvested from Lewis lung carcinoma 
cells increased the production of ROS and induced alterations in the mitochondrial ETC. 
Additionally, Bohlen et al. (2018) observed an increase in ROS production in the skeletal 
muscle of breast cancer patients. The difference observed in our results might be due to 
different cancer types that were investigated. Various cancer cells secrete different factors 
therefore specific signaling pathways in the myotubes are activated in response to this.  
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The production of free radicals and ROS is one of the mechanisms in which DXR induces its 
anti-neoplastic and cytotoxic effects on healthy cells or tissues, including skeletal muscle 
(Tacar, Sriamornsak & Dass, 2012). In the skeletal muscle, DXR targets mitochondrial ETC 
complexes and induces ROS production (Min et al., 2015). In our study, treatment of the 
myotubes with 1.6 µM DXR did induce a significant increase (p<0.001) in mitochondrial ROS 
compared to Control (Figure 3.2). These results correlate with DXR induction of 
mitochondrial stress in the myotubes observed by Gilliam et al. (2011). 
Our results showed that mitochondrial ROS in C.DXR was significantly decreased when 
compared to DXR (p<0.05) and that no difference was observed when compared to 
C.Control (Figure 3.2). This finding might suggest that the breast cancer cells were able to 
mediate DXR mitochondrial ROS production that reduced the amount of mitochondrial ROS 
produced in the myotubes. Cancer cells have been shown to maintain ROS homeostasis 
and increase anti-oxidant capacity in response to elevated ROS production (Kumari et al., 
2018). The mechanism of action in C.DXR may be an anti-oxidant response of the cancer 
cells to DXR however, further analysis of oxidative stress in both E0771 cells and myotubes 
will be required.  
 
5.2. Myotubes Integrity 
Cachexia is the skeletal muscle-wasting syndrome that has been accredited to be the cause 
of death for 20-40% of cancer patients (Tisdale, 2009). The extent of cancer cachexia that is 
induced in breast cancer patients is not fully established. Investigation of myotube atrophy, 
integrity, and morphology was completed with myotube width measurement (µm2) using the 
Cell Tracker™ Assay. Our findings showed no differences between Control and C.Control 
(Figure 3.4) therefore E0771 conditioned media did not alter myotube morphology and 
integrity after 24-hour treatment. DXR and C.DXR (Figure 3.4) did not significantly reduce 
myotube width however Gilliam et al. (2011) observed a significant decrease in myotube 
integrity when treated with 2 µM of DXR after 24-hours. While the concentration of DXR 
used by Gilliam et al. (2011) was considerably different, it may account for alterations in 
myotube due to sensitivity of in vivo studies. The downstream effects in protein expression 
and mitochondrial dysfunction, induced by cancer cells and chemotherapy, may therefore 
not have been significantly induced yet. Further analyses with longer treatment periods or at 
higher DXR concentrations will be required to determine if alterations in myotube integrity 
will occur. 
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5.3. Resistance 
Cancer cells must undergo inhibition of cell proliferation and induction of cell death in order 
for chemotherapy to be considered effective. The ability of cancer cells or tumours to 
withstand the intended anti-neoplastic and cytotoxic effects of chemotherapy is known as 
resistance. Mitochondrial reductive capacity, analyzed with a MTT assay in Figure 4.1, 
indicated the metabolic activity of active viable cells.  
Myotube conditioned media (C.Control) was observed to significantly promote cell 
proliferation and increase cell viability of breast cancer cells when compared to Control 
(p<0.01)(Figure 4.1). The introduction of the E0771 conditioned media onto myotubes did 
eliminate the influence myotubes had on cell proliferation as no alteration in cell viability was 
observed in C.C.Control when compared to Control. This was observed to be a novel finding 
which may indicate that the release of cytokines and growth factors by skeletal muscle 
promoted cancer cell proliferation. Additionally, stimuli from breast cancer cells prevented 
myotubes from releasing the factors that increased proliferation in breast cancer cells.  
The use of DXR to induced effective cytotoxic effects in breast cancer was validated as 
treatment with DXR at 1.6 µM dose in breast cancer cells significantly decreased cell viability 
(p<0.001)(Figure 4.1). As DXR produces ROS for its cytotoxic and neo-plastic effects 
(Tacar, Sriamrnsak & Dass, 2012), the increase in mitochondrial ROS observed in DXR 
(Figure 3.2) would likely have reduced the cell viability in E0771 cells (Figure 4.1).  
Unexpectedly, a significant increase in viability was observed in C.DXR (p<0.01) compared 
to DXR, however no difference in viability was observed when compared to C.Control 
(Figure 4.1). This novel finding indicates that even though mitochondrial ROS production 
was increased in myotubes following treatment of DXR, the treatment of E0771 cells with 
DXR reduced ROS production. Further analysis of oxidative stress in E0771 cells will 
determine if the mechanism is due to the anti-oxidant capacity as previously described 
(Kumari et al., 2018). Additionally, the potential factors released by myotubes that increased 
the cell viability in C.Control, in response to E0771 conditioned media, were not altered 
when myotubes were treated with DXR as equal cell viability was observed between these 
groups (Figure 4.1). Further investigation of conditioned media is required to identify the 
markers that resulted in breast cancer cell viability maintenance. 
Cell viability in E0771 cells (Figure 4.1) treated with DXR treated E0771 conditioned media 
(C.C.DXR), was observed to be significantly increased when compared to DXR (p<0.001) 
and to C.C.Control (p<0.05). As mitochondrial ROS production was not observed to be 
significantly increased in myotubes (C.DXR) (Figure 3.2), it is presumed that induction of 
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survival pathways was not due to ROS stimuli. Alternatively, the increase of cell viability in 
C.C.DXR may be due to reciprocal alterations of factors between the breast cancer cells and 
myotubes. DXR treatment of E0771 cells has been shown to release proteins that stimulate 
survival pathways such as NF-κβ, PI3K/Akt, and ERK (Buchholz et al., 2005; Zhang et al., 
2016). These proteins in the E0771 conditioned media can interact with the myotubes 
resulting in the release of additional or alternative proteins in response. When the breast 
cancer cells are treated with this myotube conditioned media, significant alterations in 
protein expression or signaling pathways were induced in the breast cancer cells. 
Downstream results of these interactions resulted in the significant increase of E0771 cell 
viability. Investigation of proliferation and apoptotic pathways will elude the modifications in 
cancer signaling pathways, that upregulated the cell viability of breast cancer cells.  
 
5.4. Proliferation 
Dysregulation in one or more proliferation pathways has been shown to promote 
unsuppressed growth. To validate the E0771 cell viability results, protein expression of cell 
proliferation markers in the PI3K/Akt pathway, ERK pathway, and a member of the MCM 
protein family was analyzed using western blot. Akt is phosphorylated for its activation and is 
a significant protein in the PI3K/Akt pathway that induces various effects that promote cell 
survival, cell proliferation, cell growth, and cell migration. Meiosis, mitosis and cell survival 
are promoted by the activation of the ERK pathway. The phospho-ERK and total ERK ratio 
indicates a fold change in the phosphorylation and activation of ERK. Increases in the ratio 
correlates to upregulation of ERK activation and downstream effects. Finally, MCM proteins 
recruit proteins involved in DNA replication and the formation of replication forks. An 
increase in MCM2 expression indicates increased induction of genome replication. The 
interactions between the PI3K/Akt pathway, ERK pathway, MCM proteins and their 
contributions to cancer progression are illustrated in Figure 5.1. 
The PI3K/Akt pathway was shown to regulate skeletal muscle atrophy in vivo, but the 
mechanism has not been fully investigated (Bodine et al., 2001). The expression of total Akt 
in Control, C.Control and C.C.Control was however observed not to be significantly different 
in our study (Figure 4.2). Accurate analysis of the activation of Akt activity and the PI3K/Akt 
pathway however could not be completed without the expression of phosphorylated Akt. 
ERK expression in skeletal muscles promotes proliferation of myoblasts as well as 
differentiation of myocytes into myotubes (VanHook, 2014). No significant difference was 
observed in the ERK fold change ratio between Control, C.Control and C.C.Control (Figure 
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4.3) therefore, even though the muscle cells were differentiated myotubes, ERK expression 
in myotubes did not cause alterations in expression in E0771 cells. Additionally, no 
difference of MCM2 expression was observed between these groups (Figure 4.4). These 
changes are noteworthy due to the significant increase of cell viability in C.Control (p<0.01) 
but not C.C.Control when compared to Control (Figure 4.1). Further investigation of the 
expression of phosphorylated Akt may reveal alterations in Akt activity that correlate with the 
increase in proliferation observed.  
DXR has been shown to trigger Akt activation in breast cancer cells (Brown et al., 2015) 
however no difference in total Akt expression was observed in our study (Figure 4.2). As 
previously discussed, future investigation of phosphorylated Akt expression may reveal 
alterations in activity. The ROS produced from DXR can stimulate growth factors, Ras 
activity and ERK 1/2 protein phosphorylation causing significant activation of the ERK 
pathway (McCubrey et al., 2007; Cheruku et al., 2015). The alterations in expression of ERK 
and phosphorylated ERK in MDA-MB-231 and MCF-7 cells due to DXR treatment were 
investigated by Taherian & Mazoochi (2012). They showed that MDA-MB-231 cells were 
more sensitive to DXR and induced a decrease in ERK 1/2 and phosphorylated ERK 1/2 
expression while alternatively, MCF-7 cells were seen to have an increase in ERK 1/2 and 
phosphorylated ERK 1/2 expression. Our results observed a significant increase in the ERK 
fold change ratio when compared to Control (p<0.001) that may reduce the sensitivity to 
DXR treatment (Figure 4.2), however significant cell death was observed (Figure 4.1). 
While activation of the ERK pathway is associated with cell growth and survival, pro-
apoptotic induction has also been observed under certain conditions (Lu & Xu, 2006). 
Currently there is little evidence of alterations in MCM2 expression due to DXR however 
DXR forms clusters of replication forks that decrease transcription (Im et al., 2014). Our 
results did not correlate with this, as no difference in MCM2 expression was observed 
(Figure 4.4). 
When C.DXR and C.C.DXR were compared to DXR, an equal and significant increase in cell 
viability was observed (p<0.001) (Figure 4.1) with no alterations in total Akt expression 
(Figure 4.2) and a significant reduction in the ERK expression ratio (Figure 4.3). These 
results show that the activation of the ERK pathway in cancer cells from DXR-induced ROS 
production (McCubrey et al., 2007) is eliminated, further supporting that ROS production and 
its downstream effects can be mediated by the anti-oxidant capacity of cancer cells. 
Alternatively, a significant decrease in MCM2 expression in C.C.DXR was observed 
compared to DXR (p<0.01) as well as C.DXR (p<0.01) (Figure 4.4). Our results indicate that 
the cells which DXR initially targets, and induces a response in, is able to mediate a 
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difference in MCM2 protein expression in breast cancer cells. This may be due to these 
microenvironments promoting replication fork cluster formation. 
An equal increase in cell viability was observed between C.Control and C.DXR (Figure 4.1) 
was supported by no difference being observed, between these groups, in the expression of 
total Akt, the ERK ratio, and MCM2. This novel finding indicated that an alteration in 
proliferation signaling and increased cell growth of breast cancer cells was a result of stimuli 
from the myotubes, irrespective of chemotherapy treatment, however the exact mechanism 
is not known. The cell viability in C.C.DXR was significantly increased when compared to 
C.C.Control (p<0.05) (Figure 4.1). This significant increase in cell viability is substantiated 
with a significant decrease in total Akt expression in C.C.DXR when compared to 
C.C.Control (Figure 4.2). As no difference in the ERK expression ratio was observed in 
these groups, our results show that the ERK pathway is not influenced by alterations 
between breast cancer cells, myotubes, and DXR (Figure 4.3). Finally, the comparison of 
C.C.Control and C.C.DXR exhibited a significant decrease in the expression of MCM2 
(p<0.01) (Figure 4.4). These findings contradict results of the significant increase in cell 
viability, as MCM proteins are responsible for transcription and regulation of the cell cycle, 
are reduced therefore a reduction of replication forks and cell proliferation. Furthermore, the 
downregulation of Akt activity has also been shown to reduce the phosphorylation of MCM2 
(Chang et al., 2003). This interaction was observed in total Akt expression of the E0771 cells 
following treatment of DXR treated E0771 conditioned media, however comprehensive Akt 
activity analysis is required. The novel findings in proliferation pathways emphasize the need 
of systemic consideration during chemotherapy as cancer cells treated with DXR prompt a 
response in myotube microenvironments with reciprocal upregulation of proliferation 
signaling in cancer cells. Further investigation into the factors present in myotube-
conditioned media will assist with potential targets to reduce cancer cell growth. 
 
5.5. Apoptosis 
A mutation that promotes rapid cell proliferation or inhibits apoptosis promotes the 
development and progression of tumours, as the damaged cells are not effectively removed. 
Apoptosis is mediated by an extrinsic and an intrinsic pathway that converge into the 
execution pathway. Chemotherapeutic drugs, including DXR, modulate apoptosis with 
multiple pathways and the increased presence of apoptotic markers in tumours after 
chemotherapy indicates induction of apoptosis (Kerr, Wylie & Currie, 1972). DXR directly 
targets components of the intrinsic pathway (Leung & Wang, 1999) and the extrinsic 
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pathway (Reed, 1994). Our study did not focus on the mechanism of induction but rather on 
the final execution of apoptosis. The fold change ratio of cleaved caspase 3 and total 
caspase 3 (Figure 4.5) as well as cleaved PARP and total PARP (Figure 4.6) indicated no 
activation of the execution pathway in C.Control or C.C.Control compared to Control. These 
results are supported by cell death not being observed in the E0771 cells (Figure 4.1). 
These novel finding indicates that myotube conditioned media components do not directly, 
or through downstream signaling pathways, induce apoptosis in breast cancer cells 
irrespective of initial stimuli from breast cancer cells. 
DXR treatment of E0771 cells did not alter the fold change ratio of caspase 3 (Figure 4.5); 
however, a significant decrease was observed in the PARP fold change ratio (p<0.01) 
compared to Control (Figure 4.6). This fold change ratio reduction indicates a decrease in 
apoptotic induction. PARP is the active form of this protein and its functions are inactivated 
by cleavage (Ouyang et al., 2012). The decrease in PARP fold change may indicate a 
reduction in the cleavage of PARP through upstream pathways or a higher expression of 
activated PARP. Hyper-activation of PARP, and thus an increase in total PARP expression, 
has been shown to a direct response of DXR activity (Tacar, Sriamrnsak & Dass, 2012). 
While a decrease of cell viability in the DXR group was observed in Figure 4.1, the 
significant decrease in the ratio of PARP expression (Figure 4.6) could be an attempt by the 
E0771 cells to repair the DNA induced by DXR for cell survival. Alternatively, an alternative 
cell death mechanism may have been induced by DXR resulting in the reduction of viability. 
Intervention of microenvironments may directly or indirectly, with the use of signaling 
pathways, inhibit apoptosis from occurring (Weinstein-Oppenheimer et al., 2001). During 
protein degradation of muscle, downstream activation of caspase 3 and the ubiquitin-
proteasome pathway have been observed (Jackman & Kandarian, 2004). A study by Gilliam 
et al. (2012) observed that exposure of myotubes to DXR has been shown to promote 
skeletal muscle catabolism with the upregulation of caspase 3 activity. In the C.DXR group, 
an increase in the fold change ratio of caspase 3 was observed but this was not significant 
due to the considerable variation observed (Figure 4.5). Additionally, cell death was not 
observed in the MTT assay (Figure 4.1) and this could possibly be explained with changes 
in PARP activity. The fold change ratio of cleaved PARP and total PARP (Figure 4.6) was 
significantly decreased when compared to C.Control (p<0.01) indicating an upregulation of 
DNA repair and a decrease in the induction of apoptosis. This repair prevented the cells 
from undergoing apoptosis and maintaining cell viability (Elmore, 2007). This novel finding 
indicated that contradictory alterations of protein expression in breast cancer cells were 
induced due to factors released by myotubes in response to chemotherapy. Additionally, the 
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hyper-activation of total PARP activity by DXR, thus reduction in PARP cleavage, is 
maintained in downstream effects irrespective of cell type and concentration. 
The fold change ratio of caspase 3 in C.C.DXR remained unaltered when compared to 
C.C.Control (Figure 4.5) indicating that there were no alterations in the factors released by 
the myotubes in response to cancer stimuli with and without DXR treatment that could 
induce apoptosis. The factors released by myotubes in response to DXR-treated cancer 
cells however, did result in alterations in DNA repair. The PARP fold change ratio observed 
in Figure 4.6 was significantly reduced compared to C.C.Control (p<0.001) but remain 
constant with expression in DXR and C.DXR. Our findings observed that DXR treatment 
decreases apoptotic signaling in both cancer cells and myotubes that can promote 
upegulation of survival signals and chemotherapy resistance in breast cancer cells. 
 
5.6. Invasion and Metastasis 
In epithelial breast cancer cells, the induction of EMT induces a mesenchymal phenotype 
that promotes migration of tumour cells and their invasion into surrounding tissue.  EMT 
activation has also been shown to stimulate apoptotic resistance, thereby encouraging 
resistance to chemotherapeutic agents. The mesenchymal markers α-SMA and vimentin are 
important proteins within the cytoskeleton. An increase in these markers has been shown to 
correspond to alterations in the cell structure that increases migratory capabilities of cells. 
The upregulation of the transcription factor SNAIL suppresses the transcription and 
expression of the epithelial marker E-cadherin. Cell-cell adhesions are broken down with the 
loss of E-cadherin promoting metastatic properties of the cell.  
No difference in the percentage of wound closure was observed between Control and 
C.Control or Control and C.C.Control (Figure 4.8). The percentage of wound closure in 
C.Control however was observed to be significantly lower compared to C.C.Control after 6-
hours (p<0.001), 12-hours (p<0.01), and 24-hours (p<0.01). The highest percentage of 
wound closure for C.C.Control was observed at 12-hour time point but closure remained 
unchanged after 24-hours. Comparison of α-SMA expression to Control exhibited a 
decrease in C.Control and a significant reduction in C.C.Control (p<0.05) (Figure 4.10). The 
significant reduction of α-SMA indicates a more epithelial phenotype in the breast cancer 
cells. These results are contradictory as migration and invasion of epithelial cancers were 
shown to correlate with an increase in α-SMA expression (Birchmeier et al., 2003). When 
observing the expression of vimentin and SNAIL (Figure 4.11 and 4.12), no difference was 
observed when comparing Control, C.Control and C.C.Control. Additionally, E-cadherin 
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expression was observed to be increased in C.Control and C.C.Control (Figure 4.13) when 
compared to Control but significance could not be determined due to variation in expression. 
Our novel findings indicate that treatment of breast cancer cells with myotube conditioned 
media could possibly induce a more epithelial phenotype, however, the significant increase 
in the percentage of wound closure of C.C.Control exhibits that reciprocal interactions 
between E0771 cells and myotubes did promote migration of the cancer cells. 
DXR percentage of wound closure was significantly higher when compared to Control at all 
time points (p<0.05, p<0.001) (Figure 4.8). No significant difference was observed in the 
expression of α-SMA, vimentin or SNAIL when compared to Control (Figure 4.10-4.12). 
These results indicate that during migration of cancer cells, the cell phenotype was not 
permanently altered to one state. An increase in E-cadherin expression was observed when 
compared to Control but as previously discussed, significance could not be accurately 
obtained due to variation (Figure 4.13). A study by Bandyopadhyay et al. (2010) has shown 
that TGF- β is upregulated by doxorubicin in metastatic murine breast cancer. Upregulation 
of TGF-β due to DXR correlates with significant dysregulation of ERK activation we 
observed in our results as an alternative induction of EMT. Investigation of TGF-β is 
however required to determine the mechanisms in which DXR induces the effects observed.  
Comparison of DXR, C.DXR and C.C.DXR exhibited no difference in percentage or rate of 
wound closure (Figure 4.8 and 4.9). Compared to DXR, the expression of α-SMA was 
decreased in C.DXR and significantly decreased in C.C.DXR (p<0.01) (Figure 4.10). As 
previously described, an increase in α-SMA is associated with increased invasion of 
epithelial cancers (Birchmeier et al., 2003) however our studies observed significant 
decrease when cancer cells were treated with E0771 treated myotube conditioned media 
with and without DXR. This novel finding indicates that myotube conditioned media was able 
to reduce α-SMA expression in E0771 cells and that this response was independent of 
chemotherapy. Additionally, the reciprocal stimulations between myotubes and E0771 cells 
further reduced the expression of α-SMA. A significant alteration in expression of any protein 
will result in alterations in cell functions therefore a significant loss of a protein responsible 
for structure and integrity (Lee et al., 2013) may result in dysfunctional morphology. This 
may additionally reduce adhesion to neighbouring cells however further investigation is 
required. Vimentin expression was observed to have been significantly increased in C.DXR 
compared to DXR (p<0.05) (Figure 4.11). An upregulation of vimentin has been shown to 
correlate with increased tumour growth and invasion (Satelli & Li, 2011). This increase in 
vimentin expression may be a downstream activation of Ras due to the significant increase 
in mitochondrial ROS in the myotubes during treatment (Vuoriluoto et al., 2010). This will 
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correlate to why no difference in expression was observed in the other treatment groups, 
however further investigation into oxidative stress within both myotubes and cancer cells is 
required. No differences were observed in SNAIL expression in a comparison between DXR, 
C.DXR and C.C.DXR (Figure 4.12). Finally, C.DXR expression of E-cadherin non-
significantly decreased compared to DXR however, no difference of expression was 
observed between DXR and C.DXR (Figure 4.13). Additionally, the E-cadherin expression 
in C.DXR was observed to be non-significantly decreased when compared to C.Control. 
A significant increase in percentage of wound closure was observed in C.DXR at all time 
points when compared to C.Control (p<0.001) (Figures 4.8). Comparison between C.DXR 
and C.Control, however exhibited no significant difference in the mesenchymal markers α-
SMA, vimentin and SNAIL (Figure 4.10-4.12). The decrease in the epithelial marker E-
cadherin observed in C.DXR (Figure 4.13) was insignificant therefore this finding indicates 
that the phenotypical profile of E0771 cells remain even though significant migration was 
induced in C.DXR. Comparison of C.C.Control and C.C.DXR exhibited no differences in 
percentage of wound closure (Figure 4.8). Alternatively, no alterations observed in the 
expression of α-SMA, vimentin, SNAIL or E-cadherin between C.C.Control and C.C.DXR 
(Figure 4.10-4.13). These findings indicate that myotubes treated with E0771 conditioned 
media, independent of DXR treatment, initiated the same migratory and EMT phenotype in 
breast cancer cells. These findings may help to understand mechanisms of metastasis and 
correlate with a study by Velikova et al (1998). They observed that while E-cadherin 
expression at tumour sites was significantly increased in patients with liver, stomach, colon, 
pancreas, ovarian, and rectal cancer, the soluble expression of E-cadherin was not 
significantly increased in the colorectal cancer patients compared to the healthy control. 
Significant differences were observed in the percentage of wound closure and rate of wound 
closure during our study (Figure 4.8-4.9) however no significant alterations in the EMT 
markers were observed (Figure 4.10-4.13). As we used Mitomycin C during our scratch 
assay, the migration observed could not have resulted due to proliferation. Breast cancer 
cell lines have been shown to undergo partial transitions rather than a terminal epithelial or 
mesenchymal state (Grosse-Wilde et al., 2015; Lambert, Pattabiraman & Weinberg, 2017). 
Additionally a study conducted by Chao et al. (2012) had shown that breast cancer 
metastases expressed E-cadherin at cellular membranes as well as retaining the expression 
of the mesenchymal marker vimentin. Partial transitions between EMT and MET could 
account for these alterations and hybrid co-expression of epithelial and mesenchymal 
markers. Control and C.Control observed very little migration after the 24-hour treatment 
period, however significant migration in wound closure was observed in C.C.Control 
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(p<0.001). In this treatment group, an increase in the percentage of wound closure was 
observed after 12-hours of treatment that was then maintained until after 24-hours of 
treatment.  Additionally the rate of wound closure %.hr1) was observed to steadily decrease 
for all treatments at each time point (Figures 4.8). This indicates that at the time point 
protein expression was analysed, the cells may potentially be in a hybrid phase as migration 
rate was decreasing. The rapid alteration may be due to stimuli from nutrients depleting or 
space restriction. In cancer cells, phenotypic plasticity is maintained to promote quick 
transition between MET and EMT in order to promote cell growth and resistance to 
chemotherapeutic treatments in metastases. Additionally, the tumour microenvironment is 
able to influence phenotypic plasticity of cancer cells and induce EMT (Jolly et al., 2017). 
The decrease of E-cadherin expression in cancer cells was observed to induce EMT and the 
promotion of invasion, however, the induction of MET and the increase of E-cadherin 
expression was necessary for the survival and migration of secondary metastasis (Louie et 
al., 2013; Ya, Peng & Dai, 2013). The significant variation of E-cadherin expression 
observed in some of our treatments groups may be a result of these alterations in the hybrid 
phenotypes. Skeletal muscle microenvironments are favorably plastic to promote rapid 
contraction and wound healing of muscle fibres (Schiaffino & Reggiani, 2011). This plastic 
microenvironment may be promoting an increased plastic phenotype in the cancer cells 
enabling migration through rapid induction of EMT followed by MET induction. The proximity 
of microenvironments has been shown to promote metastasis is correlated with the risk of 
cancer metastasis (Robinson et al., 2009). Investigation of markers at additional time points 
may reveal the dynamic alterations of EMT and MET induction in cancer cells, the influence 
of skeletal muscle plasticity on these alterations and responses to chemotherapeutic 
treatment. 
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Chapter 6 – Conclusion 
The investigation of the influence of myotube microenvironments on cancer progression and 
the chemotherapeutic response is important to reduce chemotherapy resistance and 
metastasis as these factors significantly reduce patient survival. Our study investigated the 
dynamic interactions between skeletal muscle and breast cancer following chemotherapeutic 
treatment (Figure 6.1). In our study, following treatment of myotubes with 1.6 µM DXR, a 
significant increase in mitochondrial ROS production was observed when compared to 
Control (p<0.001) while myotube integrity was preserved. Treatment of E0771 cells with 
DXR-treated myotube conditioned media (C.DXR) significantly increased the percentage of 
wound closure after 24-hours (p<0.01) and decreased the cleaved/total PARP ratio 
(p<0.001), indicating a decrease in the induction of apoptosis, when compared to the 
myotube conditioned media (C.Control). These novel findings indicated that significant 
alterations in E0771 cells by myotube-conditioned media were dependent on chemotherapy-
induced alterations, possibly as a mechanism of mitochondrial ROS production.  
Treatment of E0771 cells with 1.6 µM DXR compared to Control significantly decrease cell 
viability (p<0.001), increases the phospho/total ERK ratio (p<0.001) and decreases the 
cleaved/total PARP ratio (p<0.01). This indicates that although there was a reduction of 
viable cells, a survival pathway was induced and apoptosis reduced. Additionally, a 
significant increase in the percentage of wound closure after 24-hours (p<0.01) was 
observed indicating migration of the cells. These findings correlated with interactions and 
mechanisms of action previously observed as a result of DXR in cancer cells. Treatment of 
myotubes with DXR-treated E0771 conditioned media (C.DXR) did not result in any 
significant changes in mitochondrial ROS production or myotube integrity. Finally, following 
treatment of E0771 cells with DXR-treated E0771 myotube conditioned media (C.C.DXR), a 
significant increase in cell viability (p<0.05) and a significant decrease in expression of total 
Akt (p<0.05), MCM2 (p<0.05), and the cleaved/total PARP ratio (p<0.001) was observed 
when compared to Control-treated E0771 myotube conditioned media (C.C.Control). These 
novel findings exhibited that significant alterations in breast cancer signaling pathways were 
induced due to reciprocal interactions between breast cancer cells and myotubes as well as 
their responses to DXR. 
Our novel investigation of the dynamic interactions between myotubes and breast cancer 
cells revealed evidence of alterations in breast cancer signaling pathways that promoted 
cancer progression and cell survival. Our study also revealed novel evidence that this 
myotube microenvironment significantly affected the response of breast cancer cells to the 
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chemotherapeutic treatment of DXR. These alterations were also significantly influenced 
when the dynamic cancer-myotube-cancer interactions were investigated. While the exact 
mechanisms and responses have not yet been fully elucidated in our study, we have 
identified new target mechanisms that may reduce drug resistance and breast cancer 
metastases as these processes significantly impact the mortality of cancer patients. 
 
Figure 6.1: Proposed alterations in signaling pathways due to the dynamic relationships between E0771 
cells, myotubes and DXR treatment. Significant results observed in myotubes when DXR treatment was 
compared to Control and E0771 cell conditioned media C.DXR treatment to C.Control. Treatment of E0771 cells 
showed significant results when DXR treatment was compared to Control, myotube conditioned media C.DXR 
treatment compared to C.Control as well as myotube conditioned media following treatment of E0771 cell 
condition media C.C.DXR compared to C.C.Control. 
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Chapter 7 – Limitations and Future Studies 
 
Limitations of this study include that only one time point of cell viability and protein 
expression was investigated. This resulted in observation of alterations at that specific time 
point and not the dynamic interactions that change over time. This study only used a 
cancerous epithelial cell line, therefore comparisons to healthy mammary epithelial cells 
could not be completed. Alternate cell death mechanisms were not studied therefore only 
alterations regarding apoptosis could be investigated. Additionally, only one or two markers 
were investigated within a signaling pathway that do not accurately represent if complete 
activation of the pathway has occurred. 
Future studies that should be considered following our study include examining the 
alterations with myotubes as a consequence of cancer and DXR. Due to the mechanism of 
action induced by DXR, analyses of mitochondrial dynamics and oxidative stress within the 
myotubes and cancer cells would increase understanding the mechanisms of drug 
resistance to DXR. Determining alterations in the cell cycle phases of cancer cells and 
investigation of TGF-β and p53 regulation should also be considered as these components 
play significant roles in drug resistance and metastasis. An additional treatment of cancer 
cells with DXR, after stimulation by myotube conditioned media with/without cachexia 
phenotype, is required for future studies. This will investigate alterations in chemotherapeutic 
response of breast cancer cells due to pre-stimulation by a healthy and diseased myotube 
microenvironment. Proteomics analyses of all conditioned media collected and used will 
provide more information regarding proteins and signaling pathways activated due to stimuli 
from different microenvironments. 
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Appendix A – Supplementary Data 
Caspase 3 expression in myotubes: 
 
Figure A: Protein expression of Total Caspase 3 from western blot analysis after 24-hour treatment of 
myotubes. Myotubes were treated for 24-hours as Control, C.Control, DXR consisting of 1.6µM DXR, and 
C.DXR. Values expressed as percentage (%) of control with statistical representation as mean  ±SEM with n = 3. 
 
PARP expression in myotubes: 
 
Figure B: Protein expression of Total PARP from western blot analysis after 24-hour treatment of myotubes. Myotubes 
were treated for 24-hours as Control, C.Control, DXR consisting of 1.6µM DXR, and C.DXR. Values expressed as percentage 
(%) of control with statistical representation as mean  ±SEM with n = 3. 
35 kDa 
Total 
116 kDa 
Total 
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p62 expression in myotubes: 
 
Figure C: Protein expression of p62 from western blot analysis after 24-hour treatment of myotubes. 
Myotubes were treated for 24-hours as Control, C.Control, DXR consisting of 1.6µM DXR, and C.DXR. Values 
expressed as percentage (%) of control with statistical representation as mean  ±SEM with n = 3. *p<0.05 
compared to Control, #p<0.05 compared to DXR. 
 
LC3 expression in myotubes: 
 
Figure D: Protein expression of LC3 from western blot analysis after 24-hour treatment of myotubes. 
Myotubes were treated for 24-hours as Control, C.Control, DXR consisting of 1.6µM DXR, and C.DXR. Values 
expressed as percentage (%) of control with statistical representation as mean  ±SEM with n = 3. 
  
62 kDa 
Total 
17 & 19 
Total 
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Differentiation Media ratio’s on E0771 cells: 
 
Figure E: MTT cell viability assay completed on E0771 cells with variety of concentrations of 
differentiation media. Control consists of 50% serum free media and 50% FBS containing media, 100% 
differentiation media consist of only differentiation media, 50% differentiation media consists of 50% serum free 
media and 50% differentiation media, and 25% differentiation media consists of 25% differentiation media, 25% 
FBS containing media and 50% serum free media. 
 
 
 
α-Smooth Muscle Actin expression in myotubes: 
 
Figure F: Protein expression of α-Smooth Muscle Actin from western blot analysis after 24-hour 
treatment of myotubes. Myotubes were treated for 24-hours as Control, C.Control, DXR consisting of 1.6µM 
DXR, and C.DXR. Values expressed as percentage (%) of control with statistical representation as mean  ±SEM 
with n = 3. 
43 kDa 
Total 
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Vimentin expression in myotubes: 
 
Figure G: Protein expression of Vimentin from western blot analysis after 24-hour treatment of myotubes. Myotubes 
were treated for 24-hours as Control, C.Control, DXR consisting of 1.6µM DXR, and C.DXR. Values expressed as percentage 
(%) of control with statistical representation as mean  ±SEM with n = 3. *p<0.05 compared to Control. 
  
57 kDa 
Total 
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Appendix B - Reagents 
 
Table 1: Cell Culture Reagents 
Reagent Name Company Produced Company Purchased Cat # 
Dulbecco’s Modified 
Eagle’s Medium 
Gibco® by Life 
Technologies™ 
ThermoFisher Scientific® #41965-062 
Fetal Bovine Serum Capricorn Scientific® ThermoFisher Scientific® #FBS-G1-12A 
Penicillin-Streptomycin 
Gibco® by Life 
Technologies™ 
ThermoFisher Scientific® #15140-122 
0.25% Trypsin-EDTA 
Gibco® by Life 
Technologies™ 
ThermoFisher Scientific® #25200072 
Horse Serum Lonza BioWhittaker® #14-403F 
Doxorubicin Lasec® Lasec® #FLAS25AC2050 
MTT Powder Sigma-Aldrich® Sigma-Aldrich® #M2003 
Mitomycin C Sigma-Aldrich® Sigma-Aldrich® #M4287 
DMSO Sigma-Aldrich® Sigma-Aldrich® #D2650 
Cell tracker™ Green Invitrogen™ ThermoFisher Scientific® #C2925 
Hoechst 33342 Sigma-Aldrich® Sigma-Aldrich® #B2261 
Dako Fluorescent 
Mounting Media 
Dako Diagnostech® #S302380 
MitoSOX™ Invitrogen™ ThermoFisher Scientific® #M36009 
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Table 2: General Reagents 
Reagent Name Company Cat # 
β-Mercaptoethanol Sigma-Aldrich® #M3148 
APS Sigma-Aldrich® #A3678-25G 
Bovine Serum Albumin (BSA) Roche #10735078001 
Bromophenol Blue Merck® #SAAR1437500CB 
Coomassie Brilliant Blue G Sigma-Aldrich® #27815-25G 
Glycine Merck® #357002-1KG 
EDTA Sigma-Aldrich® #EDS-100G 
EGTA Sigma-Aldrich® #E-0396 
Nonyl phenoxypolyethoxylethanol (NP-
40) 
Sigma-Aldrich® #74385-1L 
Phenylmethylsulfonyl Flouoride (PMSF) Sigma-Aldrich® #93482-50ml-F 
Protease inhibitor Cocktail Roche #11893580001 
Sodium chloride (NaCl) Merck® #1.06404 
Sodium deoxycholate Sigma-Aldrich® #D6750-100G 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich® #L3771 
Sodium fluoride (NaF) Merck® #193270 
Sodium orthovanadate (Na3VO4) Sigma-Aldrich® #56508 
TCE Sigma-Aldrich® #T54801 
TEMED Merck® #1.10732.0100 
Tris-base Merck® #648310 
Triton-X Sigma-Aldrich® #X100 
Tween-20 Sigma-Aldrich® #P1379 
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Table 3: General Chemicals 
Chemical Name Company Cat # 
Ethanol Protea Chemicals #2207101022 
Glycerol Merck® #SAAR2676520 
Hydrochloric acid Merck® #SAAR3063040LP 
Methanol Merck® #1.06009.2500 
Phosphoric Acid Merck® #1.00573.2500 
Propan-2-ol (Isopropanol) Merck® #SAAR5075040LC 
 
 
Table 4: Protein Extraction & Western Blot Reagents 
Reagent Name Company Cat # 
Acrylamide (40%) Merck® #100640 
Bio-Rad® Enhanced Chemiluminescence 
(ECL) 
Bio-Rad® #1705061 
Bio-Rad® FastCast Gel Kit Bio-Rad® #1610185 
Bio-Rad® RTA Midi PVDF Transfer Kit Bio-Rad® #1704273 
BLUeye Prestained Protein Ladder Biocom Biotech® #PM007-0500 
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Table 5: Antibodies 
Antibody Name Company Cat # 
α-Smooth Muscle Actin Abcam® #ab7817 
AKT Cell Signalling Technology® #9272 
Anti-Mouse Cell Signalling Technology® #7076S 
Anti-Rabbit Cell Signalling Technology® #7074S 
Caspase 3 & Cleaved Caspase 3 Cell Signalling Technology® #9662 
E-cadherin Cell Signalling Technology® #14472 
ERK 1 & ERK 2 Abcam® #ab184699 
MCM2 Abcam® #ab108935 
PARP & Cleaved PARP Cell Signalling Technology® #9532 
Phosphorylated AKT (ser473) Cell Signalling Technology® #4060 
Phosphorylated ERK 1 & ERK 2 
(Thr202/Tyr204) 
Cell Signalling Technology® #4370 
SNAIL Cell Signalling Technology® #3879 
Vimentin Cell Signalling Technology® #5741 
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Appendix C – Reagent Protocols 
 
1) Complete media 
• 455mL DMEM 
• 50mL FBS (10%) 
• 5mL PenStrep (1%) 
Store at 4oC 
 
2) Differentiation media 
• 455mL DMEM 
• 5mL Horse serum (1%) 
• 5mL PenStrep (1%) 
Store at 4oC 
 
3) Isoproponal/Triton-X solution (50:1): 
Acidic Isoproponal 
• 99mL Isoproponal 
• 1mL concentrated HCl 
Triton-X 
• 0.1mL Triton-X 
• 100mL dH20 
Isoproponal/Triton-X solution (50:1) 
• 50mL 1% acidic Isoproponal 
• 1mL 1% Triton-X 
Store at RT 
 
4) MTT solution (per well): 
Light sensitive – keep MTT solution covered and switch off lights 
• Dissolve MTT in PBS to 0.01g/mL 
• Add remaining PBS (3 fold) 
• Final ratio of 1:3  -  [0.01g MTT/mL PBS] : [PBS]] 
 
5) PBS 
• 16.001g of NaCl 
• 0.400g of KCl 
• 2.882g of Na2HPO4 
• 0.481g of KH2PO4 
• Dissolve in 1.8L of dH2O 
• Adjust pH to 7.4 
• Fill up till 2L 
• Autoclaved PBS 
Store at RT 
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6) 100mM EDTA: 
• 1.4612g EDTA 
• 50 mL dH20 
• Set to pH 8 to dissolve 
Store at RT 
 
7) 100mM EGTA: 
• 1.90175g EGTA 
• 50 mL dH20 
• Set to pH 8 to dissolve 
Store at RT 
 
8) 10% SDS: 
• 50g SDS 
• Make up to 500mL with dH2O 
• Heat slightly to dissolve 
 
9) Modified RIPA Buffer (100mL): 
To 50mL dH20 
• 790mg Tris-base [± 65mM] 
• 900mg NaCl [± 154mM] 
• Stir until dissolved 
• Adjust to pH 7.4 
• 10mL of 10% NP-40 [1%] 
• 10mL of 10% Na-deoxycholate [1%] 
• Stir until solution is clear 
• 5mL of 100mM EDTA [± 5mM] 
• 5mL of 100mM EGTA [± 5mM] 
• 1mL of 10% SDS [0.1%] 
• Adjust to 100mL 
Aliquot and store in fridge 
Before use, add the following to 1 mL RIPA buffer: 
• 42µl Protease Inhibitors Cocktail 
• 5µl 200mM Na3VO4 [final 1mM] 
• 5µl 200mM NaF [final 1mM] 
• 5µl 200mM Phenylmethylsulfonyl Flouoride (PMSF) [final 1mM] (Add last! Very 
unstable in aqueous solutions) 
 
10) Bradford Reagent (5X) 
• Dissolve 500mg Coomassie Brilliant Blue G-250 in 250 mL 95% ethanol  
• Add 500 mL Phosphoric acid and mix thoroughly 
• Make up to 1L with dH2O 
• Filter and store @ 4°C 
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11) Bradford Working Solution 
• Dilute stock in 1:4 ratio with dH2O 
• Filter using 2 filter papers at the same time, until solution is a light brown colour 
Store at RT 
 
12) Laemli’s Sample Buffer (Stock Solution) (225mL) 
• Dissolve 9.09g Tris in 100 mL dH20 
• Add 6 mL 10% SDS, stir 
• Set to pH 6.8 with HCl 
• Make up to 150 mL dH20 
• In a glass beaker (not too small, approx. 400 mL) weigh off 60g glycerol 
• Add 99.9 mL of the above solution to glycerol 
• Add 26.4g SDS, dissolve thoroughly  
• Add 0.225g Bromophenol Blue, dissolve thoroughly  
• Make up to final volume of 225 mL with dH20 
Store at RT 
 
13) Laemli’s Sample Buffer (Working Solution) (1mL) 
Prepare in fumehood 
• 150ul β-mercaptoethanol 
• 850ul sample buffer  
Final concentrations when adding sample buffer to sample in ratio of 1:2 
• 62.5mM Tris, pH 6.8 
• 4% SDS 
• 10% Glycerol 
• 0.03% Bromophenol Blue 
• 5% β-mercaptoethanol 
Store at RT 
 
14) 1.5M Tris-HCl pH8.8 (1L) 
• 18.15g Tris 
• 80mL dH2O 
• Adjust pH to 8.8 using HCl 
• Make up to final volume of 1L 
Store at RT 
 
15) 0.5M Tris-HCl pH 6.8 (1L) 
• 6g Tris 
• 80mL dH2O 
• Adjust pH to 6.8 using HCl 
• Make up to final volume of 1L 
Store at RT 
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16) 10X TBS Buffer (2L) 
• 48.4g Tris 
• 160g NaCl 
• Dissolve in 1.5L dH20  
• Set pH to 7.6 with HCl 
• Adjust volume to 2L 
Store at RT 
 
17) 1X TBS-T Buffer (1L) 
• 100 mL 10x TBS 
• 900 mL dH20 
• 1 mL Tween 
Store at RT 
 
18) Glycine/Low PH Stripping Buffer (1L) 
• 15g Glycine 
• 10 mL 10% SDS 
• 10 mL Tween-20 
• 800 mL dH20 
• Adjust to pH 2.2 with HCl 
• Adjust to final volume of 1L with dH20 
Store at RT. Throw away if solution becomes cloudy 
 
19) Bio-Rad® 1X Transfer buffer  
• 600 mL Ethanol 
• 600 mL dH20 
• 300 mL 10X Transfer buffer 
Store at RT 
 
20) 10X Running Buffer 
• 10g SDS 
• 30.3g Tris 
• 144.1g Glycine 
• Dissolve in 800 mL of dH2O 
• Adjust volume to 1L 
Store at RT 
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Appendix D – Protocols 
Common volumes used for culturing 
 T25 T75 
Media 3 – 4 mL 8 – 10 mL 
Trypsin 2 mL 4 mL 
PBS 3 mL 9 mL 
 
Thawing Cells Protocol: 
Make sure everything is prepared and ready before thawing the vial and work quickly once thawed 
1. Thaw cryovial in waterbath (37o) – don’t submerge above rim of lid 
2. Add thawed cells to 15ml falcon containing 5ml media 
3. Centrifuge at 1500rpm for 3min 
4. Remove supernatant 
5. Resuspend in volume of media being used to seed flask 
6. Seed cell suspension in appropriate size flask 
7. Refresh media either later on the same day or the following day 
 
Trypsinising cells Protocol: 
1. Remove media from flask 
2. Add appropriate amount of trypsin and incubate in shaking incubator.  
§ 3 minutes for E0771 cell line 
§ 8 minutes for C2C12 cell line 
3. Tilt the flask to collect all the trypsinised cells in the corner. 
4. Remove and add to 15ml tube. 
5. Rinse flask with volume of media equal to that of the trypsin to collect remaining cells and 
transfer to 15 mL or 50mL centrifuge tube. 
6. Centrifuge at 1500rpm for 3min at 21oC. 
7. Carefully remove tube from centrifuge – check that pellet has formed 
8. Decant majority of media-trypsin. Collect the remaining with a P1000 pipet being careful not 
to disturb the pellet 
9. Resuspend in the appropriate amount of media 
§ If splitting, take the appropriate number of cells and add to a new flask containing 
media. 
 
Counting cells Protocol: 
1. Clean cell counter and cover glass with ethanol 
2. Following trypsinisation and centrifugation, resuspend pellet in an appropriate amount of 
media 
§ Based on size of pellet – want to dilute enough to be able to count comfortably but 
not too dilute (if too dilute counting will be less accurate) 
3. Make sure cell suspension is thoroughly mixed. Remove 30ul of cell suspension and add to 
both sides of cell counter 
4. Check on microscope 
5. Count three blocks on each side of counter. (Top left, top right and bottom right). 
6. Calculations 
§ Obtain average by adding totals from blocks together and dividing by six 
§ Multiply by 10 000 to give number of cells per ml. 
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§ Multiply by resuspended volume to give total number of cells. 
 
 
 
 
 
 
 
 
 
Seeding Cells Protocol: 
1. Trypsinise cells, resuspend and count 
2. Prepare master mix containing number of cells per ml and media 
3. Add the appropriate amount of cell suspension master mix to each well 
• Make sure the cell suspension is thoroughly mixed before use  
• Use new tip for each well  
• Mix tube containing cells between each well with brief shake.  
4. Mix plate to ensure cells are evenly distributed in wells – always check under microscope 
5. Incubate 
 
Freezing Cells Protocol: 
1. Prepare cells by trypsinisation and resuspend in an appropriate volume of media 
2. Count cells in suspension  
3. If multiple vials are being frozen down, the multiplied volumes of each component can be 
prepared together in a falcon first and then aliquoted into the vials 
4. After determining the total amount of cells in suspension, calculate the volumes required for 
each component of the freezing solution per vial 
§ Must freeze down at least 1.5x106 cells per vial 
§ An appropriate amount of DMSO (5%) is added to make up to a final volume (1ml – 
1.5ml, depending on size cryovial).  
§ Excess volume made up of media 
5. Add components to cryovials.  
6. Incubate for 1-4hrs at -20°C 
7. Incubation overnight at -80°C 
8. Store in liquid nitrogen cell tanks 
 
Differentiation of C2C12 Cells Protocol: 
1. Seed the required amount of cells 
2. After reaching 70% confluency, remove media and add appropriate amount of differentiation 
media to each well. 
3. Incubate in growth conditions for 48 hours 
4. Remove media and refresh with differentiation media 
5. Incubate for growth conditions for 24 hours 
6. Remove media and continue with treatment protocols 
 
1 2 
3 
Stellenbosch University  https://scholar.sun.ac.za
 102 
Treatment Protocol: 
1. Mix treatments thoroughly using using Vortex-2 Gene® 
2. Tilting plate to gather media to one area in well and remove media using pipette tip. Be 
careful not to disturb cells 
3. Pre-wet tip and add appropriate volume of master mix to edge of well 
4. Repeat for triplicate wells and use new tip for each well 
5. Repeat for all treatment groups 
6. Allow to incubate over 24 hours 
 
MitoSOX™ Protocol: 
1. Allow cell tracker dye vial to warm to room temperature 
2. Dissolve 50 µg of product in 13 µL of DMSO (Stock = 5mM) 
3. Dilute 6.5 µL of MitoSox stock with 65 µL Horse serum and 6 428.5 µL PBS (5µM) 
4. Remove media and wash cells 1x with 400 µL warm PBS 
5. Gently add 400 µL MitoSox working solution to each well 
6. Incubate plate covered in foil under growth conditions for 15 minutes 
7. Remove working solution and wash cells 1x with 400 µL warm PBS 
8. Dilute 4 µL of Hoescht stock with 7 996 µL serum free media (5µM) 
9. Add 400 µL Hoescht working stock to plate for 10 minutes 
10. Wash cells 1x with 400 µL PBS 
11. Fix cells in 4% paraformaldehyde for 10 minutes 
12. Wash cells 1x with 400 µL PBS 
13. Dry and mount with Dako fluorescent mounting media 
14. Wrap plate in parafilm and store covered in foil in fridge 
15. Image using Ex: 492 and Em: 517 
 
Cell Tracker™ Protocol: 
1. Allow cell tracker dye vial to warm to room temperature 
2. Dissolve 50 µg of product in 10.76 µL of DMSO (Stock = 10mM) 
3. Dilute 4 µL of cell tracker stock with 7 996 µL serum free media (5µM) 
4. Warm cell tracker working solution at 37°C 
5. Remove media and wash cells 1x with 500 µL warm PBS 
6. Gently add 500 µL warm cell tracker working solution to each well 
7. Incubate plate covered in foil under growth conditions for 30 minutes 
8. Dilute 4 µL of Hoescht stock with 7 996 µL serum free media (5µM) 
9. Add 500 µL Hoescht working stock to plate in final 10 minutes 
10. Remove working solution 
11. Wash cells 1x with 500 µL warm PBS 
12. Fix cells in 4% paraformaldehyde for 5 minutes 
13. Wash cells 1x with 500 µL PBS 
14. Dry and mount with Dako fluorescent mounting media 
15. Wrap plate in parafilm and store covered in foil in fridge 
16. Image using Ex: 492 and Em: 517 
 
Cell Viability Protocol: 
1. Mix MTT solution thoroughly using using Vortex 
2. Tilting plate to gather media to one area in well and remove media using 200µL pipette tip. Be 
careful not to disturb cells 
3. Pre-wet tip and add 100µL of MTT solution to edge of well 
4. Covered in foil and incubate for 1 hour at 37°C 
5. Tilting plate to gather media to one area in well and remove MTT solution using 200µL pipette 
tip. Be careful not to disturb cells 
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6. Add 100µl Isoproponal/Triton-X to wells and to blank wells 
7. Incubate for 5min on shaker 
8. Read absorbance on plate reader at 595nm 
 
Migration Scratch Assay Protocol: 
1. Mitomycin C stock solution of of 0.4 mg/mL was prepared 
2. Aliquots were made and stored at 4°C, shielded from light 
§ Not to be stored for longer than a week as precipitation forms 
3. Make three linear wounds in each well using a 200 µL pipette tip 
4. Wash each well with warm PBS to remove cell debris 
5. Add fresh growth media to each well 
6. Capture initial (T0) images of each wound and record positions on microscope 
7. Treat each well with appropriate treatment master mix 
8. Add the appropriate amount (10 µg/mL) of Mitomycin C to each well 
9. Cover plate in foil to protect from light and incubate at growth conditions 
10. Repeat capturing of images at same positions of each wound at timepoints 6-hours (T1), 12-
hours (T2) and 24-hours (T3) 
 
Protein Extraction Protocol: 
• NB! – Work on ice! 
1. Retrieve cells 
2. Remove media from cells with Pasteur pipette 
3. Wash 2x with ice-cold PBS and Pasteur pipette 
4. Add 80µL RIPA Buffer per well in 6-well plate or 150µL per T25 flask 
5. Incubate for 2-5min, on ice 
6. Using a cell scraper, scrape cells loose and collect in corner of flask 
7. Clean scraper with EtOH between different flasks 
8. Collect suspension from flask/plate and transfer to pre-cooled microtube 
9. Sonicate for 5sec @ 5 amplitude 
10. Incubate in fridge, on ice, until foam has settled (can also be stored at this point, -80°C) 
11. Centrifuge for 2min @16.3g 4°C 
12. Collect supernatant in new pre-cooled microtube 
13. Store @ -80°C 
 
Protein Determination Protocol: 
1. If needed, thaw protein samples on ice 
2. Thaw a 1mg/ml BSA stock solution 
3. Prepare BSA working solution (200µg/ml) by diluting 100µl BSA with 400µl dH2O (50ul BSA + 
450ul dH20 if using 2mg/ml BSA stock). Vortex 
4. Prepare Bradford standards as follow (in duplicate): 
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Table 7: Volumes of components used to establish Bradford standards. 
µg Protein 200µg/ml BSA dH2O Bradford Reagent 
0 (Blank) 0µl 100µl 900µl 
2 10µl 90µl 900µl 
4 20µl 80µl 900µl 
8 40µl 60µl 900µl 
12 60µl 40µl 900µl 
16 80µl 20µl 900µl 
20 100µl 0µl 900µl 
 
5. Vortex protein samples 
6. For each Bradford sample, add 5µl of protein sample to 95µl dH20 and 900µl Bradford 
reagent. Prepare samples in duplicate. 
7. Vortex Bradford samples and standards 
8. Zero spectrophotometer with blank and set @ 595nm 
9. Read absorbencies 
10. Draw standard curve in Excel graph and plot values of sample to determine [protein sample] 
 
Sample Preparation Protocol: 
1. Prepare a working solution of Laemmli’s sample buffer   
2. Prepare samples by adding the appropriate amount of protein sample to sample buffer (as 
determined with Bradford Assay) 
3. In order to give equal amounts of protein for loading = 20µg 
4. Vortex samples 
5. Store as ready-made samples @ -80°C 
Proceeding with western blot 
1. Thaw samples on ice 
2. Punch a hole in the lid of each sample 
3. Vortex samples and boil for 5min @ 95°C 
4. Vortex samples before brief centrifugation (pulse) at 1.6 g 
5. Samples now ready for loading 
 
Stain Free SDS-Page Self Cast Gel Protocol: 
1. Get clean pairs of spacer plates and short plates, Biorad casting frames (green), casting 
stands and the rubber gaskets that go in the bottom of the stand. 
2. Place gaskets in the grooves at the base of the casting stands. 
3. Clean the plates thoroughly with EtOH and place in the casting frames with the short plate 
facing to the front – secure with the clip on the casting stand.  
4. Get 3 small beakers and label for H2O, resolving gel (bottom) and stacking gel (top). 
5. Make up the required resolving gel according to the recipe to make 4 gels. 
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Table 8: Volumes of components used for self-cast resolving gel. 
Resolving Gel 
Gel constituent 12% Gel 
dH2O 8.5 ml 
40% Acrylamide solution 6.0 ml 
1.5M Tris-HCl, pH 8.8 5.0 ml 
10% w/v sds 200 µl 
10% w/v APS 200 µl 
TCE 100 µl 
TEMED (add last!) 8.0 µl 
 
6. Add all the constituents with gentle swirling to mix, except the APS and TEMED. 
7. Add the APS and swirl briefly to mix. 
8. Add the TEMED, swirl briefly to mix. 
9. Using plastic Pasteur pipette, quickly pour the gel mixture between the two plates (avoid air 
bubbles by pouring from the one corner) until the green line seen at back of plate from gasket. 
10. Top with a layer of 100% EtOH to remove bubbles, leave smooth surfaces and prevents 
oxidation. 
11. Allow gel to set (30 to 60 minutes). Prepare 1:10 dilutions of running buffer, TBS-T and 
transfer buffer. 
12. When resolving gel is set, carefully pour off the EtOH and dab dry with blotting paper. Then 
prepare the stacking gel as follows (the amounts given are sufficient for 4 gels). 
 
Table 9: Volumes of components used for self-cast stacking gel. 
Stacking Gel 
Gel constituent 4% Gel 
dH2O 4.84 ml 
0.5M Tris-HCl, pH 6.8 2.0 ml 
40% Acrylamide solution 1.0 ml 
10% w/v sds 80 µl 
10% w/v APS 80 µl 
TEMED (add last!) 8.0 µl 
 
13. Add all the constituents with gentle swirling to mix, except the APS and TEMED. 
14. Add the APS and swirl briefly to mix. 
15. Add the TEMED, swirl briefly to mix 
16. Using a plastic Pasteur pipette, quickly pour the gel mixture between the two plates until top 
of front plate. 
17. Insert appropriate comb gently, pushing down and avoiding bubble formation (make sure 
comb corresponds to the gel thickness). 
18. Allow to set for 30 minutes. 
19. Retrieve the standard protein marker from the freezer and allow to equilibrate to room 
temperature. 
 
Stellenbosch University  https://scholar.sun.ac.za
 106 
Stain Free SDS-Page Fast Cast Gel Protocol: 
Using Bio-Rad® TGX Stain-Free™ FastCast™ Acrylamide Kit, 12%. 
Follow steps 1 – 4 of self cast gel protocol (Protocol f.3) 
1. Make up the required resolving gel according to the recipe given by Bio-Rad® to make 4 gels. 
 
Table 10: Volumes of components used for self-cast resolving gel. 
Resolving Gel 
Gel constituent 4% Gel 
Resolver A 12 mL 
Resolver B 12 mL 
TEMED 12 µL 
10% APS 120 µL 
 
1. Add all the constituents with gentle swirling to mix 
2. Using plastic Pasteur pipette, quickly pour the gel mixture between the two plates (avoid air 
bubbles by pouring from the one corner) until the green line seen at back of plate from gasket. 
3. Allow gel to set (30 to 60 minutes). Prepare 1:10 dilutions of running buffer, TBS-T and 
transfer buffer. 
4. Prepare the stacking gel according to the recipe given by Bio-Rad® to make 4 gels. 
• Do not have to wait for resolver to set first before adding stacker 
 
Table 11: Volumes of components used for self-cast stacking gel. 
Stacking Gel 
Gel constituent 4% Gel 
Stacker A 4 mL 
Stacker B 4 mL 
TEMED 8 µL 
10% APS 40 µL 
 
1. Add all the constituents with gentle swirling to mix 
2. Using a plastic Pasteur pipette, quickly pour the gel mixture between the two plates until top 
of front plate. 
3. Insert appropriate comb gently, pushing down and avoiding bubble formation (make sure 
comb corresponds to the gel thickness). 
4. Allow to set for 1 hour. 
 
SDS-PAGE Running Protocol: 
1. Prepare BioRad Fast Cast Stain-Free gels or Self Cast according to instructions 
• Gels can be made beforehand and stored in the fridge in wetted paper towels and sealed 
in cling wrap 
2. Thaw protein samples on ice 
• Prepared in 2:1 ratio of protein sample + Laemli’s buffer 
3. Punch hole in lid of microtube, mixed by vortexing briefly and boil for 5 min at 95°C 
4. Spin samples down with quick pulse 
5. Assemble the gasket 
• Assemble the gels onto the gasket with the comb facing inside 
• Fill the gasket with running buffer – check for leaks 
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• Carefully remove the combs and rinse out wells with P200 pipet (set to approx. 100 
ul) and yellow tip 
6. Load ladder (4 ul BLUeye) 
7. Load samples 
8. Place gasket into tank and fill with running buffer. Re-fill gasket if necessary 
9. Attach lid (black on black, red on red) and plug into power pack 
10. Run at 100 V for approx. 10 min (until sample has entered gel) 
11. Increase to 150 V and run until blue dye front reaches the bottom of the gel (approx. 1 hr) 
12. When finished, activate immediately  
13. Activate stain-free properties of gel on ChemiDoc  
• Gel activation protocol, 2.5 min 
 
Western Blot Transfer Protocol: 
1. Prepare for transfer (few min beforehand) 
• Soak two pieces of Bio-Rad blotting paper in transfer buffer for 2 - 3 min 
• Activate piece of PVDF membrane in 100% methanol (10-15 sec) and then soak in 
transfer buffer for 2 min. 
2.  Assemble the transfer sandwich on the cassette base (anode) by placing one piece of 
blotting paper on the bottom, then the membrane, then gel, and finally, the second blotting 
paper on top. Use the blot roller to remove air from between the assembled layers. 
3. Once the stacks are positioned in the cassette base, place the cassette lid on the base. The 
lid is reversible, but ensure that the electrical contacts fit closely into the slots in the base. 
Press the lid down firmly and turn the dial clockwise to engage the lid pins into the locking 
slots.  
4. Load a second cassette if desired. 
5. Slide the cassette (with the dial facing up) into the bay until it makes contact with the 
magnetic interlock and you hear a click. Cassettes can be inserted into the bays in any order, 
with or without power to the system.  
6. Select the LIST button from the Home menu and the MIXED MOLECULAR WEIGHT transfer 
protocol from the Bio-Rad pre-programmed protocols or the user-defined protocol of choice.  
7. To initiate the run, press the navigation button that corresponds to A:RUN for the cassette in 
the upper bay or B:RUN for the cassette in the lower bay.  
8. After transfer, disassemble stack 
• Gel can be visualised to determine transfer efficiency if desired 
9. Label membrane and rinse in 100% methanol 
• Labelling – only use soft pencil (black art pencil works well) and not markers or pens 
(causes smudges) 
• Place membrane only on ethanol cleaned surface (white tray from Chemidoc works 
well) 
10. Air-dry membrane  
• Becomes white 
• Hold in fumehood for quicker drying 
11. Re-hydrate membrane in 100% methanol 
• Until translucent, 10-15 sec 
12. Wash membrane in TBS-T for 5 min 
13. Image transfer on membrane on Chemidoc 
• Stain-free blot setting 
• If using for normalisation, make sure image is clean and not over-exposed 
 
Western Blot Antibody Protocol: 
1. Block membrane in 5% milk (prepared in TBS-T) for 1 hr with gentle shaking 
• Or 5% BSA (prepared in TBS-T) for when probing for phosphorylated proteins 
2. Wash membrane 3x for 5 min in TBS-T 
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3. Incubate membrane on primary antibody at 4°C for 36-hours 
§ Prepared in 50 ml centrifuge tube 
§ Dilute antibody in TBS-T to desired concentration, normally 1:1000 
§ Attach to rotators in walk-in fridge 
4. Retrieve membranes 
• Stored primary antibody in fridge/freezer 
5. Wash membrane 3x 5 min in TBS-T 
6. Incubate membrane on secondary antibody for 1 hr at RT 
§ Prepared in 50 ml centrifuge tube 
§ Dilute antibody in TBS-T to desired concentration, normally 1:10 000 
7. Wash membrane 3x 5 min in TBS-T 
8. Develop 
§ Prepare minimum amount of ECL needed in microtube in 1:1 ratio  
§ Place membrane on Chemidoc and check position 
§ Add ECL to the desired area and roll to ensure even spread. Roll away excess ECL 
a. Expose using desired settings 
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Science is a beautiful gift to 
humanity 
We should not distort it 
- A. P. J. Abdul Kalam 
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